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For more than a decade, the deoxylxylulose phosphate (DXP) pathway 
has been used to produce many commercially valuable isoprenoids. This 
thesis is focused on engineering both the pathway and the global 
environment to maximize isoprenoid production and attempts were made 
to gain a better understanding of the underlying biochemical mechanisms. 
In the first part of the study (Chapter 2), the hypothesis that the availability 
of a vital precursor (phosphoenolpyruvate, PEP) of the DXP pathway 
played a significant role in the production of isoprenoids was tested. The 
underlying rationale was that PEP is known to be consumed by the 
phosphotransferase system (PTS) when carbohydrates are imported and 
hence deletion of the PTS should increase intracellular PEP concentration 
thereby resulting in the enhancement of isoprenoid production. As 
expected, the replacement of the PTS with the ATP-consuming glucose 
transport system (galactose permease and glucose kinase) significantly 
improved production yield of various isoprenoids. In addition, the 
systematic optimization of the expression of glucose uptake pathway and 
the DXP pathway further improved the product yield by more than 190 fold 
over the control, demonstrated the power of global optimization. 
Building on the PTS knockout strain, the critical media compositions were 
screened in lycopene-producing strain using factorial design of 
experiments. Glycerol and KH2PO4 were found to be critical components 
for high yield lycopene production. Aided by response surface 
 XII 
methodology, the lycopene production was maximized at a particular 
optimal concentration of glycerol and KH2PO4. Consequently, our 
optimized medium significantly outperformed all the commonly used 
complex and defined media (Chapter 3). Using real-time qPCR, the 
transcriptional analyses of the expression of genes in the DXP and the 
lycopene biosynthetic pathways revealed that transcripts in the latter 
pathway were highly expressed due to an increase in plasmid copy 
number in our optimized media. These results highlight the significance of 
the media optimization and provide insight into the underlying 
mechanisms of media optimization. 
Using the tools we developed, the product titer increased significantly. 
However, product inhibition becomes a significant challenge as the 
product titer increases and this limits further improvement and scaling up 
of the process. To address this issue, we screened the native multidrug 
resistant transporters in E. coli (Chapter 4). Using single gene knockout 
mutants, we found that tolC was closely involved in the efflux of 
amorphadiene. The deletion of tolC entrapped the majority of AD inside 
the cells and significantly decreased extracellular AD. This was the first 
time that AD was demonstrated not to be passively secreted through the 
membrane of E. coli but effluxed by the aid of a transporter. Furthermore, 
it was found that supplementation of tolC-msbA, tolC-emrAB, tolC-emrKY 
or tolC-macAB can enhance the AD titer by more than 3 fold. The use of 
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transporters may be useful for the production of cytotoxic compounds in E. 
coli.  
Flux determination is one of the major challenges in metabolic engineering 
and the key to quantitatively understand enzymes and pathways and for 
the design of de novo pathways. We developed a semi-closed dual-flux 
platform to monitor the metabolite intermediates in the DXP pathway 
(Chapter 5). Using this platform, we managed to capture the kinetic 
behaviors of the pathway and found that the efflux rates were dependent 
on the intracellular concentration of the metabolites, almost linearly 
correlated. This platform which we have developed to gain an 
understanding of the kinetics of DXP pathway and the observation of the 
correlation of the efflux rate and intracellular concentration pave the road 
to understand the DXP pathway quantitatively in the future.
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Chapter 1. Thesis description 
1.1 Challenges in metabolic engineering 
Metabolic engineering offers a sustainable approach for the production of 
various compounds from inexpensive and renewable starting materials, 
including bulk chemicals, fine chemicals, drugs and biofuels. The objective 
of metabolic engineering is that developing cell/cell-free systems and 
fermentation/scaling-up processes to obtain products/processes with high 
TRY (high Titer, high production Rate and high Yield) from renewable 
resources, thus both economic viable and environment friendly. In order to 
obtain high TRY, we need to optimize both strains and processes. First, 
strain improvement includes: enhancing substrate uptake, providing more 
precursor supply, cofactor balancing, minimizing side reactions, blocking 
intermediate secretion from cells, coping the toxicity of both intermediates 
and products and blocking unwanted allosteric regulations by 
understanding the biological mechanisms. (Figure 1-1). Second, the global 
environment, including medium and process controlling, has to be 
optimized specifically for the improved hosts. Although strain improvement 
is the foundation of metabolic engineering, the global environment control 
is non-trivial but very critical in minimizing the product costs and 
determining the economic viability of certain process or product. Therefore, 
it is urgently required an integrated platform for combining strain 
optimization and environment optimization.  
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Figure 1-1. Objectives and challenges in metabolic engineering.  
Multiple enzymatic reactions introduced into hosts can have undesirable interactions with 
these engineered pathways, including metabolite toxicity, intermediate loss via secretion 
or side reactions, unwanted allosteric regulation and product toxicity due to accumulation 
of high concentration products. On top of strain optimization, the medium and process 
has to be developed for the optimized strain. And an integrated platform is required to 
combine strain optimization and environment optimization.  
 
1.2 Objective of this thesis 
In this thesis, multiple approaches/platforms were developed to address 
the challenges listed in Figure 1-1 in metabolic engineering. Although 
these approaches and platforms were demonstrated in the production of 
two isoprenoids (lycopene, the antioxidant and amorphadiene, the 
precursor of antimalarial drug artemisinin) in E. coli, the 
approaches/platforms developed in the thesis are generally applicable for 
optimizing other pathways and the production of metabolites/proteins and 
underlying mechanisms discovered in the thesis are applicable for 
Thesis description 
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understanding regulations and interactions in cells in metabolic 
engineering and synthetic biology.  
First, the precursor PEP was identified for the first time as a limiting factor 
in the DXP pathway and its availability was increased through engineering 
carbon uptake pathway. To address the toxicity of accumulated 
intermediates and to enhance the carbon fluxes in the DXP pathway, the 
approach of experimental design aided systematic pathway optimization 
(EDASPO) was developed to systematically optimize large number of 
modules simultaneously. Second, to enhance the product titer and to 
decrease the product cost, an integrated platform was developed by 
improving strain using EDAPSO and statistically optimizing the medium 
and cultural conditions. Third, to deal with the product toxicity, a platform 
was developed for screening multidrug resistant transporters and 
engineering transporters for cytotoxic isoprenoid production. Lastly, a 
semi-closed dual-flux platform (SCDFP) was established to monitor the 
concentration of intracellular and extracellular metabolite intermediates. 
This platform and the observed correlation of the efflux and intracellular 
concentration allow us to understand quantitatively the isoprenoid pathway 
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1.3 Description of the thesis 
In the thesis, multiple approaches were explored and established to 
enhance the yield of isoprenoids production (lycopene and AD) in E. coli 
using the DXP pathway and to understand the kinetic behaviors of the 
DXP pathway in vivo. In chapter 3, substrate engineering by deleting the 
PTS was combined with pathway optimization. Replacement of the PTS 
with galP-glk improved the yield of AD significantly (~6 fold). The EDASPO 
approach was developed and applied to optimized a four-module system 
by controlling the expression of glucose-uptake enzymes (galP-glk), the 
rate-limiting enzymes of the DXP pathway (dxs and ispDF-idi) and the 
downstream farnesyl diphosphate (FPP) synthase and AD synthase (ispA-
ads), resulted in more than 550 fold increase in AD production. In chapter 
4, the integrated platform was developed to optimize lycopene production 
by optimizing the growth conditions (media composition, temperature and 
oxygen feeding) with strain optimization (PTS knockout and pathway 
optimization). Reverse engineering was applied to gain insight into how 
media optimization increased the production of these isoprenoids. In 
chapter 5, native multidrug resistant efflux pumps in E. coli were screened 
using single knockout mutants to identify transporters involved in export of 
AD and the identified pumps were overexpressed and combined to 
improve the production of AD. In chapter 6, a well-designed experiment 
captured the kinetic data of both intracellular and extracellular 
intermediates of the DXP pathway using a SCDFP developed in this thesis 
Thesis description 
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and the S-system was attempted to model the dynamics of the system. 
Chapter 7 described the conclusion and future works. 
 
 
Figure 1-2. Overview of the thesis. 
Part I PTS knockout and engineering glucose uptake pathway. Part II, experimental 
design aided systematic pathway optimization (EDASPO). Part III, Efflux pumps was 
screened and engineered to enhance amorphadiene titer. Part IV, a semi-closed dual-flux 
platform (SCDFP). Part V, An integrated platform by integrating strain optimization and 
process optimization. The approached developed in the thesis was able to produce AD 
and lycopene at the highest “TRY” in literature (details were not put into the thesis due to 
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Chapter 2. Literature review 
2.1 Literature review 
Isoprenoids (or terpenoids) constitute one of the most diverse classes of 
secondary metabolites in nature, with more than 55,000 distinct 
compounds. This class of compounds include numerous flavors, 
fragrances, pharmaceuticals, pheromones and even biofuels [1]. 
Isoprenoids could serve various functions such as membrane structure 
(sterols, hopanoids), hormones (gibberellins), light harvesting and 
photoprotection (chlorophylls, carotenoids), electron carriers (ubiquinone, 
plastoquinone), and mediators of polysaccharide assembly, as well as 
communication and defense mechanisms [2, 3]. The various biological 
functions of isoprenoids are related to their diversified structures. 
Some isoprenoids are long-chain linear hydrocarbons (e.g. lycopene), 
while most of them exhibit complex structures having chiral, cyclic 
skeletons (e.g. Taxol). Based on the number of carbon atoms, isoprenoids 
are classified as hemi- (C5), mono- (C10), sesqui- (C15), di- (C20), ses- 
(C25), tri- (C30), tetra- (C40) and poly- (> C40) isoprenoids. The demand 
for some isoprenoids (e.g. Taxol as anticancer drug, artemisinin as anti-
malaria drug and lycopene as nutraceutical, Figure 2-1) is on the rise and 
there is a global shortage due to limited supply from natural sources like 
plants. For example, it would require the entire bark of a 100-year old 
Taxus brevifola tree to extract a single dose of Taxol [4]. Market 
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fluctuation and environmental changes have further exacerbated the 
problem and this resulted in a growing demand for a sustainable supply of 
these isoprenoids [5, 6]. Total chemical syntheses of isoprenoids have 
been successful but face significant challenges including low yield due to 
their highly complicated structures (especially with compounds that have 
multiple chiral centers). Alternatively, metabolic engineering of microbes 




Taxol Lycopene Artemisinin 
 
Figure 2-1. Chemical structure of lycopene, artemisinin and taxol 
 
2.1.1 Metabolic engineering 
Metabolic engineering is defined as the directed modulation of metabolic 
pathways using methods of recombinant technology for the purpose of 
producing biofuels, bulk and fine chemicals and pharmaceuticals [8]. An 
important objective in metabolic engineering is to be able to produce 
compounds (drugs, bulk chemicals, fuel and biopolymers) from 
inexpensive carbon source (e.g. sucrose, starch and cellulosic biomass) in 
a sustainable, renewable and economical way (Figure 2-2). To be cost 
effective and commercially viable, three important parameters, namely 
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With the development of next-generation sequencing technology and 
‘omics’, previously unrecognized metabolic reactions have now been 
identified and the number of pathways to be explored has increased 
tremendously. Databases of genes, metabolic reactions and enzymes 
have broadened our capabilities to develop de novo design of biosynthetic 
pathways using computational tools [10]. The recent development of high-
throughput analytic tools has enabled us to decipher “–omics” (genomes, 
transcriptomes, proteomes, metabolomes and fluxomes) at system level 
and has led to the appreciation of “system metabolic engineering” [11]. In 
addition, reverse engineering, integrated with specific perturbation or 
random genetic modifications, have helped to probe the causal network 
that links genotype and phenotype and to develop better metabolic 
engineering strategies [12]. To summarize, the strategies of metabolic 
engineering in literature are categorized in Figure 2-2, ranging from 
synthetic biology to protein engineering to pathway engineering. 
 
Table 2-1. Intuitive rational approaches and systematic combinatorial approaches. 
Intuitive rational approaches Systematic combinatorial approaches 
Precursor enrichment and balancing 
Elimination of the competing and/or degrading 
pathways 
Rerouting metabolic pathway 
Engineering of carbon source utilization 
Transporter engineering 
Cofactor optimization 
Multivariate-modular pathway engineering 
RNA or protein scaffold-based spatial 
optimization 
Global perturbation of genome or transcriptome 
Directed evolution and enzymatic evolution 
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Figure 2-2. Metabolic engineering as a synthesis of synthetic biology and protein and 
pathway engineering. Reproduced with permission of the copyright owner [9]. 
 
From another perspective, these strategies can be grouped into two 
categories: Intuitive rational approaches and systematic combinatorial 
approaches [11]. Intuitive rational approaches are mainly used to solve 
well-defined problems and thus more intuitive. While systematic 
combinatorial approaches are applied to improve the overall performance 
of cells that are treated as a global network with high complexity (Table 
2-1). 
2.1.1.1 Intuitive rational approaches in metabolic engineering 
1. Precursor enrichment and balancing 
A common approach in metabolic engineering to increase the availability 
of precursors in cells is by overexpressing rate-limiting enzymes (e.g. 
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Taxol [13], levopimaradiene [14], plant alkaloids [15], lycopene [16], L-
valine [17], artemisinin [18]). In addition, balancing the supplys and 
demands of precursors are also very important when more than one 
precursor is required. For example, all the isoprenoids are built from two 
units, isopentenyl diphosphate (IPP) and dimethylallyl diphosphate 
(DMAPP). IPP isomerase (idi) is the enzyme which catalyzes the inter-
conversion of relatively un-reactive IPP to more-reactive electrophile 
DMAPP. Idi gene was shown to play an important role in balancing the 
ratio of IPP and DMAPP and improving the isoprenoid production [19-21]. 
Similarly, balancing of the fluxes of the two precursors of the 1-deoxy-D-
xylulose-5-phosphate (DXP) pathway (the pyruvate and glyeraldehyde-3-
phosphate) was shown to increase the lycopene production significantly 
[22-24]. 
2. Elimination of the competing and/or degrading pathways 
Elimination of competing pathway to enhance the flux through the desired 
pathway is another commonly used approach in metabolic engineering. 
There are numerous successful examples using this approach, especially 
in the production of primary metabolites (e.g., succinic acid [25], lactic acid 
[26] and amino acids [27]). Two recent examples where the deletion of 
acyl-CoA synthetase genes improved the production of fatty acid-derived 
biofuels and chemicals in Saccharomyces cerevisiae [28], and the deletion 
of aspA gene which blocked the conversion of fumaric acid into L-aspartic 
acid increased the production of fumaric acid [29]. 
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3. Rerouting metabolic pathways 
This approach contains two aspects: the first is to search for more efficient 
or substrate-specific enzyme via heterologous expression of enzymes 
from various sources. For example, to increase the yield of plant alkaloids, 
the l-DOPA-specific decarboxylase from Pseudomonas putida strain 
KT2440, which exhibited greater than 103-fold preference for l-DOPA in 
comparison to other aromatic amino acids, was selected to replace the 
less specific monoamine oxidase [15]. The second aspect is to construct 
new biosynthetic pathways. For instance, 1-Butanol titer was increased 10 
fold by engineering a modified 1-butanol pathway with an irreversible 
reaction catalyzed by trans-enoyl-coenzyme A (CoA) reductase that 
created NADH and acetyl-CoA as driving forces to direct the flux [30]. 
4. Engineering of carbon source utilization 
To reduce the cost, different approaches have been applied to enhance 
the uptake efficiency of carbon sources in microbes. A bi-level 
optimization algorithm, SIMUP, was developed to find metabolic 
engineering strategies to efficiently use lignocellulosic biomass which 
contains both pentose (xylose) and hexose (glucose) [31]. Likewise, the 
inactivation of the carbohydrate phosphotransferase system (PTS) has 
been demonstrated to increase the aromatic products by preserving more 
phosphoenolpyruvate (PEP) [32].  
5. Transporter engineering 
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Removal of products from reaction system can alter the equilibrium of 
chemical reactions. Export of products into extracellular space through 
native/engineered transporters can play a similar role. In addition, this 
export process can minimize feedback inhibition and accumulation of 
products to potentially toxic levels intracellularly. Engineering of efficient 
transporters successfully improved the tolerance of hosts to toxic and/or 
high-yield products (e.g. biofuels) [33-35] and further increased production 
(e.g. carotenoids) [36].  
6. Cofactor optimization 
Many redox enzymes catalyze synthetic reactions which commonly 
require precursors and cofactors, such as NADPH, NADH and ATP. The 
synthesis of certain products may be limited by the availability of cofactors 
or the imbalance of redox. Thus, cofactors engineering has been 
investigated and successfully applied to increase the yield of various 
products (polyphenols [37], lycopene [38], thymidine [39], succinate [40]). 
For example, NADPH pool was increased by deletion or attenuation of 
glycolytic enzymes which redirected metabolic flux through the pentose 
phosphate pathway [37, 41], or the replacement of central metabolic 
enzyme that produced NADPH instead of NADH [42, 43]. 
2.1.1.2 Systematic combinatorial approaches 
1. Multivariate-modular pathway engineering 
Overexpression of single rate-limiting enzyme cannot result in optimal 
production for most of the metabolic pathways, and global balancing of the 
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expressions of multiple enzymes is a useful approach [44]. To search for 
the optimal balance between pathway expression and cell viability, 
synthetic promoters libraries [45] or tunable intergenic regions libraries 
(e.g. RBS, mRNA secondary structures) has been explored [46, 47]. A 
good example is that of taxadiene production which was increased 
~15,000 fold through a systematic optimization of upstream and 
downstream modules [13].  
2. RNA or protein scaffold-based spatial optimization 
Multi-enzymatic pathways are often spatially organized into scaffolds, 
clusters or microcompartments [48]. Three-dimensional organization and 
optimization can concentrate reactants to drive unfavorable reactions [49], 
minimize loss of intermediates due to diffusion, protect unstable 
intermediates from solvent and/or decrease the transit times of 
intermediates [50]. Synthetic RNA or protein scaffold has been designed 
to optimize pathway through spatial optimization, which resulted in 48-fold 
increase in hydrogen production [51] and 77-fold increase in mevalonate 
production [50].  
3. Global perturbation of genome or transcriptome 
Compared to intuitive rational approaches, combinatorial approaches can 
be more effective through exploiting biodiversity and high throughput 
screening [52]. The approach of random mutagenesis (introduced by 
chemical mutagens or ultraviolet light followed by screening of strains) has 
been employed extensively for the generation of industrial strains for many 
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decades [53]. Extending this approach, reverse engineering (or inverse 
engineering) was introduced which involves genome sequencing the 
improved phenotypes and finding out the mutation sites and then to 
engineer the genotypes. The information obtained from sequencing is 
critical to decipher regulatory mechanisms and to find multiple 
knockout/overexpression targets, or mutational site of enzymes. 
Understanding the underlying biochemical mechanism can direct future 
engineering work to further improve the performances of phenotypes.  
Nowadays, many approaches have been developed to generate large-
scale libraries of genomic mutants in a relative short time (a few days), 
which greatly facilitate the subsequent screening and sequencing 
analyses. For example, multiplex automated genome engineering (MAGE) 
was developed for large-scale programming and evolution of cells by 
simultaneously targeting many locations on the chromosome. Using 
MAGE, over 4.3 billion combinatorial genomic variants were created per 
day which enormously expanded the genotype library [54]. Trackable 
multiplex recombineering (TRMR), which generated a mixture of barcoded 
mutants, was successfully applied to identify genes that improved the 
tolerance of lignocellulosic hydrolysate [55]. Global transcription 
machinery engineering (gTME) was another method developed to 
reprogram transcriptome of prokaryote and eukaryote. gTME has been 
successfully applied to increase ethanol tolerance and lycopene 
production of Escherichia coli (E. coli) through mutating the sigma factor 
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[56] and the ethanol tolerance of S. cerevisiae via mutating TATA-binding 
protein (encoded by SPT15) and one of the TATA-binding protein-
associated factors (TAF25) [57].  
4. Directed evolution and enzymatic evolution 
Directed evolution has been used for years to improve solvent tolerance of 
strains [33], growth rate of mutated or stressed strains [41], and enzyme 
performance (e.g. turnover number kcat and/or catalytic efficiency kcat/Km 
[14], substrate and/or product specificity [58] and thermostability [59]). 
Improvement of enzyme activity via enzyme evolution has the advantage 
of introducing less stress to cells with lower expression but higher activity. 
In contrast, overexpression of enzyme may lead to the formation of 
inclusion bodies which have no or little activity and thus affects the cell 
growth and performance [60]. 
Most of the aforementioned approaches are technically distinct and may 
be combined for possible use to synergistically improve productivity.  
2.1.2 Isoprenoid synthesis pathway and Escherichia coli 
platform  
In nature, isoprenoids are derived from two basic units, isopentenyl 
diphosphate (IPP) and dimethylallyl diphosphate (DMAPP). IPP and 
DMAPP are synthesized from two pathways, the mevalonate (MVA) and 
the DXP pathway (or MEP pathway) (Figure 2-3). The MVA pathway is 
present in eukaryotes (all mammals, the cytosol and mitochondria of 
plants, and fungi) archaea, and a few eubacteria [61]. While the DXP 
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pathway exists mainly in eubacteria, cyanobacteria, green algae, 
apicomplexan parasites and higher plants [62]. Interestingly, plants have 
both pathways, located in different cellular compartments. 
E. coli is a favorable platform for recombinant proteins [63], chemicals and 
biofuels [64, 65], due to numerous advantages, e.g., well-characterized 
genetics and metabolism, rapid growth rate, lots of genetic tools and 
databases and easy to scale up in production. In E. coli, IPP and DMAPP 
are synthesized through the DXP pathway. DXP pathway starts from two 
precursors, pyruvate and glyceraldehyde-3-phosphate (GAP). Pyruvate 
and GAP are catalyzed by DXP synthase (dxs) to produce DXP and CO2. 
DXP reductoisomerase (dxr) converts DXP into methylerythritol phosphate 
(MEP) using NADPH as the cofactor. The gene IspD, ispE and ispF 
encode 4-diphosphocytidyl-2-C-methyl-D-erythritol (CDP-ME) synthase 
(CMS, which catalyzes CDP-ME from MEP and CTP), CDP-ME kinase 
(CMK, which converts the ATP-dependent phosphorylation of CDP-ME to 
4-diphosphocytidyl-2-C-methyl-D-erythritol-2-phosphate (CDP-MEP)) and 
2-C-methyl-D-erythritol-2,4-diphosphate (MEC) synthase (MCS, which 
produces CDP-MEP into MEC), respectively. IspG gene encodes 1-
hydroxy-2-methyl-2-(E)-butenyl-4-diphosphate (HMBPP) synthase (HDS) 
that catalyzes the formation of HMBPP from MEC. IspH encodes 4-
hydroxy-3-methyl-2-(E)-butenyl-4-diphosphate reductase (IDS) that 
transforms HMBPP into a 5:1 mixture of IPP and DMAPP. Lastly, IPP 
isomerase (coded by gene idi) interconverts IPP and DMAPP in E. coli 
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(Figure 2-3). The MVA pathway uses seven enzymatic reactions to 
transform the precursor acetyl-CoA to IPP and DMAPP, through five 
intermediates, acetoacetyl-CoA, 3-hydroxy-3-methylglutaryl-CoA (HMG-
CoA), mevalonic acid, mevalonate-5-phosphate, mevalonate-5-
diphosphate (Figure 2-3). 
Both MVA and DXP pathways have been exploited industrially for the 
production of isoprenoids in yeast and bacteria. Currently, research 
groups using the MVA pathway have produced high titer of isoprene [66]. 
The MVA pathway was completely described in 1967 [67]. In contrast, the 
DXP pathway was discovered relatively recently [62] and has not been 
well studied, especially with respect to the iron-sulfur cluster enzymes 
ispG and ispH which are poorly characterized [68-71]. Though 
optimization of the DXP pathway is challenging, the DXP pathway is worth 
pursuing because of the more efficient use of carbon, with 30.2% 
theoretical yield when using glucose versus 25.2% for the MVA pathway, 
as demonstrated in Table 2-2. 
 
Table 2-2. Comparison of theoretical yields of the DXP and MVA pathway 
Pathways Biochemical equation Theoretical yield 
MVA 1.5 Glucose + 2 O2 Æ IPP + 4 CO2 + 5 H2O 25.2% 
DXP 1.25 Glucose + 0.5 O2 Æ IPP + 2.5 CO2 + 3.5 H2O 30.2% 
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Figure 2-3. 1-deoxy-D-xylulose-5-phosphate (DXP) and mevalonate (MVA) pathway. 
 Enzymes in the DXP pathway, dxs, DXP synthase; dxr, DXP reductase; ispD, CDPME 
synthase; ispE, CDPME kinase; ispF, CDPMEP synthase; ispG, HMBPP synthase; ispH, 
HMBPP reductase; idi, IPP isomerase. Enzymes in the MVA pathway, AAS (erg10), 
acetoacetyl-CoA synthase; HMGS (erg13), HMG-CoA synthase; MK(erg12), mevalonate 
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2.1.2.1 Lycopene and amorphadiene 
In this thesis, two particular isoprenoids, lycopene (non-volatile metabolite) 
and amorphadiene (volatile metabolite) were chosen as examples to 
demonstrate the platforms developed in this thesis. 
The recent changes in the food regulation and labelling rule has resulted 
in the increase in demand of natural colorant as food additives and 
nutraceuticals. As a natural reddish pigment, lycopene can potentially 
replace many colours traditionally produced by chemical synthesis (e.g. 
carmine). As an antioxidant compound, lycopene is also a nutraceutical 
with various health benefits and can be used as food and drink additives. 
As a powerful free radical quencher, lycopene is also applied as skin 
protectant in cosmetics to reduce the damage from skin exposure to 
sunlight [66]. In addition, there is evidence from phase I and II clinical trials 
indicates that lycopene is a potential chemoprotective agent for prostate 
cancer [67-70]. Recent study indicates that lycopene supplementation and 
tomato uptake can lower the risk of cardiovascular disease [71]. 
Therefore, the global market lycopene is expected to increase to $84M in 
2018 from $66M in 2010, according to a recent BCC research.  
Amorphadiene is the precursor of artemisinin. Artemisinin is naturally 
produced by a plant, Artemisia annua, and it was identified as the active 
compound responsible for antimalarial properties of Artemisia annua 
extracts by Chinese scientists in the 1970s [72]. It was estimated that 
there were 219 million cases of malaria reported and 660,000 malaria-
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associated deaths occurred in 2010, and about 90% of malaria death 
occurred in Africa [73]. Many malaria-endemic developing nations have a 
per capita healthcare expenditure of under $100. In other words, a much 
cheaper and sustainable supply of artemisinin is required. Semi-synthetic 
artemisinin project funded by a grant from the Bill and Melinda Gates 
Foundation are under developing. 
2.1.3 Substrate utilization engineering  
Lignocellulose biomass is viewed as potential feedstock for future 
production of chemicals and fuels [74]. Lignocellulose hydrolysate 
contains glucose and xylose as the two major carbon sources. The 
problem of using lignocellulose is that microbe such as Saccharomyces 
cerevisiae is unable to utilize the xylose or that microorganism such as E. 
coli uses this sugar mixture sequentially and hence the yield and 
productivity are limited [75]. To tackle this problem, substrate utilization 
engineering is introduced in two aspects, one is for the engineering of the 
strains to use unfavorable carbon sources, and the other is to make more 
efficient use of carbon resource.  
1. Engineering microbes to use xylose and pentose simultaneously 
The sequential use of sugar mixture in E. coli is closely related to the 
phenomenon of carbon catabolite repression (CCR). CCR is regulated by 
EIIA in the carbohydrate phosphotransferase system (PTS). As shown in 
Figure 2-4, glucose is internalized mainly by the PTS using PEP as 
phosphate donor. In this process, the ratio of PEP/Pyruvate decreases, 
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thus EIIA is mainly dephosphorylated and inhibits the expression of 
protein adenylate cyclase (AC). The repression of AC prevents the 
production of cyclic AMP (cAMP) and thus the cAMP-CRP complex 
cannot be formed, resulting in the inhibition of the promoters of many 
catabolic genes and operons including xylose uptake genes. To disrupt 
this regulation and to co-utilize sugar mixture, ptsG (coding EIIC) can be 
deleted and this resulted in the simultaneous utilization of glucose and 
lactose [76]. Inspired by this work, a ptsG mutant was applied to co-utilize 
glucose, xylose and arabinose and achieved a 94% theoretical yield of 
ethanol [77]. In addition to ptsG, deletion of mgsA [78] or crp [79] was also 
reported to facilitate the co-utilization of glucose and xylose. An approach 
to co-culture two kinds of engineered E. coli was applied where one strain 
used glucose but not xylose and the other used xylose but not glucose 
[80].  
Recently, a rational bi-level optimization algorithm, SIMUP, was developed 
to predict the knockout mutant strains which have to use xylose and 
glucose simultaneously [31]. Based on the prediction of SIMUP, seven 
solutions were found and grouped into three strategies, A, B and C (Figure 
2-5). In strategy A, the synthesis of only glucose-6-phosphate (G6P) was 
from glucose, and all the remaining precursors were from xylose. LMSE1, 
the mutant with three genes (pgi, gnd and eda) deleted, was constructed 
to validate the strategy A (Figure 2-5A). However, the predicted mutant 
LMSE1 did not co-utilize glucose and xylose, but consumed xylose alone, 
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and this could be due to either G6P was not a biomass precursor or the 
mutant could synthesize G6P from xylose. Strategy B was a group of five 
solutions in which synthesis of only ribose-5-phosphate (R5P) was from 
glucose and only xylulose-5-phosphate (X5P) was from xylose. A three-
gene (pgi, rpe and eda) mutant, LMSE2, was constructed to validate the 
strategy (Figure 2-5B). As predicted, LMSE2 co-utilized glucose and 
xylose very efficiently. Strategy C is not intuitive as strategy A and B. The 
mutant LMSE5 was constructed based on the solution with four reaction 
disrupted by deletion of the following genes, pgi, gnd, fbp, and pfk (Figure 
2-5C). Deletion of pgi and fbp prevented gluconeogenic flux, and 
disruption of gnd stopped entry of glucose into pentose phosphate 
pathway. In agreement with the SIMUP prediction, the mutant co-utilized 
glucose and xylose in batch cultivation.  
The advantage of SIMUP is that co-utilization phenotype was achieved 
without any prior knowledge of the regulatory mechanisms involved in 
CCR. This is especially useful when the targeted mutations in the 
regulatory pathways is yet to be identified. 
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Figure 2-4. Glucose and xylose uptake pathway in E. coli 
In wild type E. coli, glucose is mainly transported by the PTS. The PTS is composed of 
three distinct proteins: enzyme I (EI), histidine protein (HPr) and enzyme II (EII). EI 
initiates the phosphorylation chain by autophosphorylating with phosphoenolpyruvate 
(PEP). The phosphoralated EI transfers the phosphyl group to Hpr, and the phosphryl 
group is subsequently donated to EIIA, finally to EIIB and from there to the carbohydrate 
through the membrane domain EIIC. EIIA is also named as catabolite repression 
resistance (crr), which regulates the carbon catabolite repression (CCR). When glucose 
is abundant, the phosphryl group is drained from PEP to glucose through EIIA, thus the 
concentration ratio between PEP and pyruvate (PYR) is low, and EIIA is dominantly 
dephosphorated. On the contrary, when glucose is absent, the ratio PEP/PYR is high, 
and EIIA is mainly phosphoralated. Phosphoralated EIIA activates membrane-bound 
protein adenylate cyclase (AC), and AC converts ATP into cyclic AMP (cAMP). The 
produced cAMP binds cAMP receptor protein (CRP, also called catabolite gene-activator 
protein (CAP)) and forms cAMP-CRP complex. The cAMP-CRP complex activates the 
promoters of many catabolic genes and operons (e.g. xylose uptake gene) [81]. Two 
pathways exists in E. coli for the uptake of xylose, xylFGH and xylE. XylFGH is ATP-
binding cassette transporter with high affinity and it’s the major transporter for xylose; 
xylE is D-xylose proton symporter which uses the proton gradient as a source of energy 
[82]. The expression of XylFGH and xykE is under the regulation of CRR. The 
abbreviations in the figure are, PTS, The phosphotransferase system; XylE, D-xylose 
transport system (low affinity); XylFGH, D-xylose transport system (high affinity); XylA, 
Xylose isomerase; XylB, Xylulokinase; PPP, Pentose phosphate pathway; AC, Adenylate 
cyclase; Glf, Glucose facilitator from Z. mobilis; GalP, galactose permease; Glk, glucose 
kinase; cAMP receptor protein; CRR, Catabolite repression resistance 
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Figure 2-5. Predicted solutions by the SIMUP algorithm.  
Based on how each solution splits the metabolic network, they have been divided into 
three strategies: (A) Strategy A in which glucose is used to synthesize glucose-6-
phosphate and all other metabolites are synthesized from xylose. Among the three gene 
combinations shown, the highlighted (red) solution was used to construct mutant LMSE1. 
Deletion of pgi blocked glucose to enter glycolysis. Disruption of gnd prevented glucose 
from entering pentose phosphate pathway (PPP) and the synthesis of glucose from PPP. 
Finally, deletion of eda stopped glucose from synthesizing glyceraldehyde-3-phosphate 
(GAP), which could be channeled into glycolysis. (B) Strategy B has five solutions. The 
highlighted solution was used to construct the mutant LMSE2. Glucose was used to 
synthesize ribose-5-phosphate and xylose was used to synthesize xylulose-5-phosphate, 
and using these two metabolites all the remaining biomass precursors were synthesized. 
(C) Strategy C contains three solutions. The four gene deletion strategy highlighted was 
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2. Efficient use of glucose with the PTS knockout 
The uptake of glucose by the PTS requires equal amount of PEP as the 
phosphate donor, and this leads to inefficient use of glucose for the 
production of certain compounds (e.g. recombinant proteins [83], 
aromatics [32], lysine [84], L-phenylalanine [85] and succinate [86]) as 
PEP is the important precursor (Figure 2-4). To address the limited 
availability of PEP, PEP synthase (ppsA) was overexpressed to recycle 
PEP from pyruvate [87]. Another way was to disrupt the PTS while other 
pathways were used to transport glucose [32, 38, 83, 85, 88, 89]. PTS 
disruption resulted in slower growth of E. coli. To increase growth rate, 
adaptive evolution was explored to screen fast-growing strains lacking the 
ptsHIcrr operon [32, 38]. Another solution was to overexpress galactose 
permease (galP) and glucokinase (glk) which facilitated the internalization 
and phosphorylation of glucose, respectively [90, 91]. 
PEP is a vital precursor for the DXP pathway, and the increase in PEP 
concentration by genetically rerouting central metabolism has been shown 
to enhance the production of lycopene [22]. Since PEP is consumed by 
the PTS when carbohydrates are imported [92], it is worth investigating 
whether deletion of PTS would increase intracellular PEP concentration 
which may result in the enhancement of isoprenoid production. 
2.1.4 Optimization of metabolic pathways 
In metabolic engineering, it is well known that overexpression of single 
rate-limiting enzyme cannot lead to globally optimized pathway and thus 
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balanced expression of multiple enzymes is required [93, 94]. Fine-
controlled pathway can regulate the concentration of intermediates thus 
eliminate their toxicity/inhibition and maximize the production [46, 95]. 
Pathway balancing can be viewed as the extension of traditional method 
of overexpressing rate-limiting genes. The rate-limiting gene is actually 
context-dependent, e.g., when the rate-limiting enzyme is overexpressed, 
another one may serve as the new rate-limiting step. Therefore, 
identification of the rate-limiting steps often requires multiple steps which 
is time consuming [19]. Combinatorial/modular approach can solve this 
issue by simultaneously controlling the expression of multiple enzymes 
thus expediting the process. 
Two recent studies have demonstrated the usefulness of this approach. 
One was the sequential optimization of the MVA pathway to produce 
amorpha-4,11-diene (AD) [96]. The whole pathway was grouped into three 
parts, MevT operon which controls the upstream genes, AtoB, HMGS and 
HMGR, MBIS operon which controls the downstream genes (MK, PMK, 
PM, idi and ispA) and AD synthase (ADS) (Figure 2-6A). 
The upstream pathway was firstly optimized by codon optimization and 
replacement with a stronger promoter. Replacing the promoter of ADS 
with a stronger one further increased the AD production. Next, rate-limiting 
step (MK) in the MBIS operon was identified by overexpressing each gene 
individually, and the codon-optimized MK was incorporated into the 
system, resulting in higher productivity.  
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The other example was the production of Taxol precursor using 
multivariate modular metabolic engineering (MMME) [13]. The authors 
assembled the DXP pathway (including dxs, ispD, ispF and idi) into the 
upstream module and the geranylgeranyl pyrophosphate (GGPP) 
synthase and taxadiene synthase into the downstream module (Figure 
2-6B). Simultaneously controlling the three different-strength promoters 
(Trc, T5 and T7) or different gene copy numbers (1 copy in chromosome, 
~5 copies, ~10 copies and ~20 copies in pSC101, p15A or pBR322 
plasmid, respectively), the upstream pathway and downstream pathway 
were well balanced that a global maximum exhibited a 15,000-fold 
increase in the titer of taxadiene over control (Figure 2-6C). This approach 
also facilitated the discovery of indole accumulation that was later shown 
to be detrimental to isoprenoid production. This observation demonstrated 
that MMME could also be applied to survey the regulations in the 
expression of heterologous pathways. 
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Figure 2-6. Illustration of modules of the MVA and DXP used for production of AD and 
taxadiene. 
(A) Production of AD via the mevalonate pathway. The abbreviations for enzymes and 
pathway intermediates are as follows: AtoB, acetoacetyl-CoA thiolase; HMGS, HMG-CoA 
synthase; tHMGR, truncated HMG-CoA reductase; MK, mevalonate kinase; PMK, 
phosphomevalonate kinase; PMD, mevalonate pyrophosphate decarboxylase; Idi, IPP 
isomerase; IspA, FPP synthase; ADS, AD synthase; IPP, isopentenyl pyrophosphate; 
DMAPP, dimethylallyl pyrophosphate; FPP, farnesyl pyrophosphate [96]. (B) Schematic 
of the two modules, the native upstream MEP isoprenoid pathway (green) and synthetic 
taxadiene pathway (red). (C) Schematic of the multivariate-modular isoprenoid pathway 
engineering approach for probing the non-linear response in terpenoid accumulation from 
upstream and downstream pathway engineered cells. Expression of upstream and 
downstream pathways is modulated by varying the promoter strength [1 (Trc), 2 (T5) and 
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2.1.5 Transporter engineering 
Many heterologous products (e.g. biofuel) are toxic to microbes, and this 
product toxicity is one of the major problems that prevent successful 
commercialization by microbial production [36]. To enhance tolerance of 
the strains and improve the yield of products, one efficient strategy is to 
recruit membrane transport protein pumps to export/secrete intracellular 
biofuels out of the cells [98]. Successful efflux of products can improve cell 
viability and enhance the production and productivity by alleviating product 
inhibition. The successful application of efflux pumps depends severely on 
successful identification of the appropriate pumps for the desired products. 
For example, the ygaZH genes encoded a protein which shows significant 
homology to the known Corynebacterium L-valine exporter and could be a 
potential pump for L-valine in E. coli. And co-overexpression of the lrp 
(which can activate the expression of ygaZH) and ygaZH genes led to a 
2.13-fold increase in L-valine production [17]. Transcriptome analyses 
revealed that the expression of rhtC gene (encoding a threonine exporter) 
in threonine-producing strain was increased as compared to control strain. 
Overexpression of rhtC resulted in 50.2% increase in theronine production 
[27]. 
However, most of the pumps involved in the export of the desired products 
are currently unknown. To facilitate screening of pumps involved, different 
screening approaches have been applied. One example is the 
bioinformatics-assisted screening approach where 43 heterologous pumps 
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were screened using competition-based strategy Figure 2-7A and B. Efflux 
pump-expressed strains were grown individually and then pooled in equal 
proportion. The pooled culture was grown in the presence of biofuel for 96 
h (controls are without biofuel) and was serial diluted every 10–14h. At 
each dilution time point, plasmids of each efflux pump from the culture 
were isolated and quantified using a custom microarray. The strains 
expressing pumps that export biofuel have growth advantage, therefore, 
these strains dominated the culture after a few generation of growth. 
Using the screening method, a previously uncharacterized pump from 
Alcanivorax borkumensis was identified and the strain expressing this 
efflux pump increased the limonene production by more than 50% [35].  
The ATP-binding cassette (ABC) exporters can export a diverse range of 
hydrophobic molecules such as lipids, drugs, and steroids. And ABC 
transporters are widely found in all five kingdoms (bacteria, cyanobacteria, 
diatoms, yeast, and algae) [99], thus they have the potential for cross-
species application. Recently, a study screened 19 bacterial ABC 
transporters to enhance the export of carotenoids. It was proposed that 
the localization of heterologous carotenoids was akin to that of lipid A, 
thus ABC transporter could help to secrete carotenoids out of the inner 
membrane (Figure 2-7C). The more efficient transporters for zeaxanthin 
and canthaxanthin were Salmonella enterica Serovar typhymurium MsbA 
and Escherichia coli MsbA, respectively. When transporters were 
overexpressed, the secreted zeaxanthin and canthaxanthin (concentration 
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in the organic layer) improved ~2.4 fold and ~4.4 fold, respectively. 
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Figure 2-7. Screening approaches used for transporter engineering in literature. 
(A) Schematic of competition-based strategy [35]. Different strains with individual efflux 
pump were grown independently and pooled in equal proportion. The pooled culture was 
grown both with and without biofuel, with a few steps of dilution into fresh media. When 
plasmids isolated, the plasmids providing growth advantage became overrepresented in 
the culture. (B) Simulations of competitive exclusion [35]. Strains with growth advantage 
dominate the population during co-culture. In contrast, the growth rate of each strain 
won’t be affected when grown separately. (C) Schematic representation of the biofuel 
secretion system [36]. The authors hypothesized that the export of carotenoids cross 
inner membrane (IM) to periplasmic space (PS) is similar to the lipid A using msbA. And 
the carotenoids partitions from the PS to organic layer through the out membrane (OM). 
(D) Directed-evolution approach used to generate tolerance-conferring variants of the 
AcrB efflux pump [34]. E. coli expressing the libraries of AcrB variants were subjected to 
growth competition in the presence or absence of 0.5% n-butanol. Following that, cells 
from both pools were plated and individual clones were tested for growth performance in 
n-butanol. After confirming AcrB variant-conferred growth, another round of mutation and 
selection was performed. Reproduced with permission of the copyright owner. 
 
Screening can identify pump candidates for various products. However, 
the pumps may not be highly efficient. Thus, a directed evolution-based 
method was used to improve the efficiency of transporters towards certain 
compounds [33, 34]. Indeed, variants of acrB were found to confer 
improved efficiency of efflux of n-octane [33] and n-Butanol [34]. By 
sequencing, the mutated sites of the acrB variant were identified and 
correlated to the improved activities. 
 
2.1.6 Kinetics modeling  
Flux determination is one of the useful tools in metabolic engineering. 
Reliable flux estimation is very informative and can be used to identify the 
rate-limiting enzymes in a pathway [9]. Successful flux analysis is highly 
dependent on the availability of reliable (less noisy and relatively 
complete) experimental data. Isotopic tracer-based approach has been 
used to understand the flux distribution in the network [100, 101]. When 
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detailed information about the kinetics of metabolic reactions is available, 
we may be able to describe the dynamics in Equation 1-1.The crucial step 
of combining stoichiometric property with kinetic features is the search for 
appropriate function to represent v. There are three major categories to 
represent v, (1) mechanistically based functions (e.g., law of mass action, 
Michaelis–Menten law); (2) ad hoc approaches; and (3) different types of 
canonical models (e.g., Generalized Mass Action (GMA), BST and lin-log 
representations), and details about these approaches were described in 
the review [102].  
The equation of mass action is shown in Equation 1-2, and the method is 
typically used to describe reaction networks consisting of elementary 
reactions. However, most biochemical reactions are not elemental but 
composites of several elementary equations [103]. 
S-system structures, a form of Biochemical Systems Theory (BST), is one 
of promising model in metabolic engineering. The model is constructed by 
approximating flux with products of power-law functions. The generic form 
of S-system formulation is shown in Equation 1-3. There are numerous 
publications using this model to understand gene regulatory networks 
[104-109] and numerous novel algorithms were developed to estimate the 
parameters [110-115]. For example, Liu et al [111] successfully used the 
S-system model to describe a batch fermentation process. Gautam et al 
[116] and Jia et al [117] developed new algorithms for the S-system model 
based on the NMR data from the L. lactis pathway. 
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                                    Equation 2-1 
where S is a vector of metabolite concentrations and v is a vector of 
fluxes. The sstoichiometric matrix N is the core of stoichiometric models 
that show how metabolite concentrations change over time. 
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                          Equation 2-2 
where k is the rate constant, which is always positive, gi are kinetic orders 
which are non-negative integer numbers that reflect the numbers of 
molecules involved in the reaction, and Xi denotes the concentration or 
amount of a variable or variable pool and n is the total number of time 
dependent variables in the system. 
1 1
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               Equation 2-3 
where Xi represents a time-dependent variable (metabolite) and n denotes 
the number of variables in the system. The non-negative multipliers Įi and 
ȕi are rate constants which quantify the turnover rate of the production or 
degradation, respectively. The real numbers gij and hij are kinetic orders 
that reflect the strengths of the effects that the corresponding variables Xj 
have with a given flux term.  
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Chapter 3. OPTIMIZATION OF GLUCOSE 
UPTAKE AND THE DXP PATHWAY FOR 
ISOPRENOID PRODUCTION  
3.1 Introduction 
Glucose is the most abundant and widely used carbon and energy source 
for microbial processes. In E. coli, glucose is transported into cytoplasm 
mainly through the carbohydrate phosphotransferase system (PTS). The 
PTS is composed of enzyme I (EI), histidine protein (HPr), sugar-specific 
enzyme IIA (EIIA) and enzyme IICB (EIICB), coded by ptsHIcrr operon 
and ptsG gene, respectively. A phosphoryl group is transferred from PEP 
to EI and HPr, then to EIIA, EIIB and EIIC. Finally, the phosphoryl group is 
transferred to glucose by the integral membrane permease EIIC [81]. In E. 
coli, half of the PEP produced from glucose is further metabolized into 
pyruvate during the glucose uptake by the PTS. PEP is an important 
precursor to produce certain industrially interesting compounds, such as 
succinate [86, 118], aromatic compounds via shikimate-pathway [32]. 
Inactivation of the PTS has been used to improve the yield of desired 
products via increasing the availability of intracellular PEP [32, 86, 118]. 
However, disruption of the PTS resulted in decreased glucose uptake and 
extremely slow cell growth rate (from 0.7 to 0.1 hr-1) when glucose was the 
only carbon source used in fermentation [38]. To address this issue, 
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adaptive evolution was used to select a fast-growing strain [32]. 
Transcriptome analysis of these fast-growing strain showed that 
transcriptional levels of the gene galP (coding for galactose permease), 
glk (coding for glucose kinase) and pgi (coding for phosphoglucose 
isomerase) were increased when compared to the wild-type strain, 
suggesting that these genes were important to enhance glucose uptake 
[91, 119]. Therefore, galP and glk were overexpressed to enhance the 
growth rate of microbes growing in glucose medium [91, 120] and the 
yields of valuable products such as aromatics [121], recombinant protein 
[122] and ethanol [90]. Combinatorial modulation of galP and glk gene 
expressions have been used to improve growth rates [120], but it is 
unknown if such an approach will increase the production of isoprenoids. 
Optimization of the activities and expressions of enzymes in a pathway is 
essential to improve product yield. Optimized pathway can minimize the 
accumulation of intermediate metabolites with potential cytotoxicity and 
thus decrease the metabolic burdens and increase the final product titer 
[46, 96]. Multivariate-modular approach to balance metabolic pathway has 
been successfully used to systematically search for the optimal conditions 
for increasing productivity [13]. Tuning plasmid copy number or 
engineering different types of promoters [123] has been used to control 
and balance the expression of multiple genes. However, these reported 
approaches are time-consuming and resource demanding, often do not 
cover the whole search space for identifying optimal conditions which 
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results in suboptimal productivity. To address this unmet need, our group 
has developed another approach, the Univariant Extrinsic Initiator Control 
System for microbes (µ-UNEICS), which controls multiple modules 
(metabolic pathway) simultaneously using T7 variant promoters with 
different transcriptional efficiencies [124]. 
In this study, to test the hypothesis that AD production from glucose was 
limited by the availability of PEP. PEP synthase (ppsA) was 
overexpressed and this resulted in the improvement of AD yield by 
increasing the intracellular concentration of PEP. Subsequently, the PTS 
was deleted and the glucose uptake pathway comprising the GGS was 
overexpressed. Unlike the use of PTS, the use of the GGS did not divert 
PEP for other side reactions and can be directly shuttled to improve AD 
production. Furthermore, systematic pathway optimization using µ-
UNEICS approach to globally optimize the four modules enabled the 
production of high amounts of AD.  
3.2 Results 
3.2.1 Increasing AD yield by ppsA overexpression 
In this study, the native DXP pathway in E. coli was used to produce AD 
(Figure 3-1). The DXP pathway starts from pyruvate and glyceraldehyde-
3-phosphate (GAP). It was reported that GAP was limiting in the 
biosynthesis of lycopene via the DXP pathway, and redirecting flux from 
pyruvate to GAP can enhance the lycopene yield [23]. To test the 
OPTIMIZATION OF GLUCOSE UPTAKE AND THE DXP PATHWAY FOR ISOPRENOID 
PRODUCTION 
Page 38 | 196 
 
hypothesis that overexpression of ppsA can help in the production of AD 
by converting pyruvate back into GAP through PEP, endogenous ppsA 
was overexpressed in MG1655 DE3 strain with T7 promoter. High 
expression of ppsA is toxic and negatively affected the growth of E. coli, 
thus moderate amount of the inducer IPTG was added to induce the 
expression of ppsA (IPTG concentration was not greater than 0.03 mM). 
As shown in Figure 3-2, the AD titer (mg/L) increased about 2 fold (from 
10 mg/L to 20 mg/L) when ppsA was overexpressed in all the conditions 
(different concentrations of IPTG). And the specific yield of AD increased 
from about 2.5 mg/L/OD to around 3.5 mg/L/OD. The result strongly 
suggested that increasing intracellular PEP concentration was likely to be 
beneficial to the AD production, since ppsA can catalyze pyruvate back to 
PEP.  
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Figure 3-1. Global control and balancing of metabolic pathway for AD production. 
T7, TM1, TM2 and TM3 promoters were used to fine controlling the expression of the four 
different modules (galP-glk, dxs, ispDF-idi and ispA-ADS). The transcriptional efficiencies 
of TM1, TM2 and TM3 were 92%, 37% and 16% of that of T7 promoter, respectively. The 
abbreviations for metabolites in the figure: glucose (GLC), glucose-6-phosphate (G6P), 
glyceraldehyde 3-phosphate (GAP), phosphoenolpyruvate (PEP), pyruvate (PYR), 1-
deoxy-D-xylulose 5-phosphate (DXP), 2C-methyl-D-erythritol 4-phosphate (MEP), 4-
diphosphocytidyl-2C-methyl D-erythritol (CDPME), 4-diphosphocytidyl-2C-methyl D-
erythritol 2-phosphate (CDPMEP), 2C-methyl-D-erythritol 2,4-diphosphate (MEC), 
hydroxylmethylbutenyl diphosphate (HMBPP), isopentenyl diphosphate (IPP) and 
dimethylallyl diphosphate (DMAPP), geranyl diphosphate (GPP), farnesyl pyrophosphate 
(FPP), amorpha-4,11-diene (AD). The abbreviations for enzyme-coding genes in the 
figure: PTS enzyme IIBC (ptsG), histidine protein (ptsH), PTS enzyme I (ptsI), PTS 
enzyme IIA(crr), galactose permease (galP), glucose kinase (glk), phosphoenolpyruvate 
synthetase (ppsA), DXP synthase (dxs), DXP reductase (dxr), CDPME synthase (ispD), 
CDPME kinase (ispE), CDPMEP synthase (ispF), HMBPP synthase (ispG), HMBPP 
reductase (ispH), IPP isomerase (idi), farnesyl pyrophosphate (FPP) synthase (ispA) and 
ADS synthase (ADS). 
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Figure 3-2. Effect of enhanced expression of ppsA on the AD production. 
 MGG01 strain is the control without overexpressing ppsA, while ppsA is overexpressed 
in MGG02 strain. (A) AD titer (mg/L). (B) Cell density of AD-producing strains. (C) 
Specific yield of AD (mg/L/DO). 
 
3.2.2 Increasing AD yield by overexpressing galP and glk 
PEP enrichment by overexpressing ppsA increased AD production. And 
glucose uptake via the PTS consumes half of PEP produced from 
glucose. This inspired us to study the effects of using alternative glucose 
uptake pathways on the AD production. Unlike the PTS which uses PEP 
as phosphate donor, the GGS transports and phosphorylates glucose 
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the GGS in the wild type strain (MGG) resulted in an increase in AD titer 
by more than 3-fold (from 10 mg/L to 37 mg/L) as compared to wild type 
strain (MGG01). With overexpression of the GGS in the PTS knockout 
mutant (PGG), AD titer was further increased by 70% to ~60 mg/L. And 
the specific yield of AD increased from about 7 mg/L/OD (MGG) to around 
12 mg/L/OD (PGG). The results indicated that the route of glucose uptake 
did affect the AD production, and the ATP-dependent GGS (PGG) was 
better than the PEP-dependent PTS (MGG01) for the AD production in E. 
coli. Noteworthy, the cell density was similar for the three strains in most 
of the conditions except that the cell density of MGG and PGG was 
exceptionally low when high concentration IPTG was used. This suggests 
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Figure 3-3. The effect of glucose uptake pathway (the GGS and/or the PTS) on AD 
production. 
MGG01 is the wild type strain which used the PTS to uptake glucose. MGG is the GGS-
overexpressed strain which used both the PTS and the GGS to uptake the glucose. 
While PGG is the PTS knockout mutant with the GGS overexpressed, thus the glucose 
was uptaken solely by the GGS. (A) AD titer (mg/L). (B) Cell density of different strains. 
(C) Specific yield of AD (mg/L/DO). 
 
3.2.3 Optimization of the expression of the GGS 
The replacement of the PTS with the GGS increased the AD production. 
Because the high expression of the GGS resulted in slightly better specific 
production but was shown to be toxic to cells, it is worth investigating 
whether tuning the expression of the GGS can further increase the cell 
density and thus the AD production. Therefore, the T7 promoter of the 
GGS in strain PGG was replaced with weaker promoters, TM1, TM2 or 
TM3, where transcriptional strength was about 92%, 37% and 16% of the 
strength of T7 promoter, respectively. TM1, TM2 and TM3 promoters were 
generated as described in the patent [125]. In the strains PGG, PGG01, 
PGG02 and PGG03, all the genes dxs idi, ispA and ADS were controlled 
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TM3 in strain PGG, PGG01, PGG02 and PGG03, respectively. As a 
result, the AD titers in strains PGG01 and PGG02 increased by more than 
3 fold as compared to that in PGG (with T7), from 60 mg/L to 200 mg/L 
(Figure 3-4). In addition, the specific yield was also slightly increased 
significantly from ~13 mg/L/OD to ~18 mg/L/OD, which means that better 
tuning of the GGS benefits both cell density and the performance of the 
DXP pathway. However, similar to strain PGG, although the expression 
levels of the GGS was decreased using the weaker promoters, the cell 
density of strain PGG01, PGG02 and PGG03 was still very low when 
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Figure 3-4. Further increase of AD production based on the model prediction. 
In strain PGG01, PGG02 and PGG03, the galP-glk was placed under control of TM1, 
TM2 and TM3 promoter, respectively. And all the others genes were placed under the 
control of T7 promoter. (A) AD titer (mg/L). (B) Cell density of different strains. (C) 
Specific yield of AD (mg/L/DO). 
  
Table 3-1. Reported AD production in literature 
# AD titer 
AD 
yield AD Productivity Host Literature 
 




0.0004 Bacillus subtilis Zhou, K., et al. (2013) 
2 27.4 
 
0.17 Escherichia coli 
Tsuruta, H., et al. 
(2009) 
3 41 17.0% 0.35 
Saccharomyces 
cerevisiae 
Westfall, P. J., et al. 
(2012) 
4 4  3% 0.1 Escherichia coli This study 
 
3.2.4 Differential control of gene expressions in the multi-
modules encoding enzymes in the glucose uptake, DXP 
and AD synthesis pathways 
A two-module optimization of the upstream DXP pathway and 
heterologous downstream terpenoid–forming pathway increased Taxol 
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GGS increased the AD yield, we hypothesized that the global pathway 
optimization of the GGS, the DXP and AD synthesis pathways may further 
increase AD production. The genes dxs, ispDF and idi were identified to 
encode enzymes that are rate-limiting in the DXP pathway [19], and the 
overexpression resulted in improved  yields of carotenoids [16, 19] and 
Taxol precursor [13]. In addition, ADS was reported as the rating-limiting 
step for the AD production [44, 96]. All these rate-limiting enzymes with 
glucose-uptake enzymes were divided into four distinct modules. The first 
is galP-glk, which regulates the uptake of glucose. The second is dxs, 
which diverts the carbon flux from central metabolic pathway into the DXP 
pathway. The third is ispDF-idi, in this module ispDF facilitates the 
conversion of intermediates of DXP pathway and idi is critical for the 
balancing of isopentenyl diphosphate (IPP) and dimethylallyl diphosphate 
(DMAPP). The last is ispA-ADS, and ispA and ADS are the last two steps 
which carry out the conversion of IPP and DMAPP into AD via farnesyl 
pyrophosphate (FPP).  
All the four modules were controlled simultaneously under the T7 or T7 
variant promoters (Figure 3-1). There would be 44=256 constructions in 
total if we did the full combination and there would be 256x4=1024 
conditions with 4 different concentration of IPTG. To be cost and time 
effective, a limited combination of constructions was chosen based on the 
following rationale. To cover a broad range, each module was controlled 
by three different promoters (TM1, TM2 and TM3). And each promoter for 
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each module was repeated at least three times (for example, TM1 for the 
first module was used in four different constructions). As a result, 14 
constructions were chosen (Figure 3-5D). As shown in Figure 3-5A, 
through the fine tuning of the four modules, AD titer increased significantly 
from about 0.36 mg/L (strain P1717 with 0.03 mM IPTG) to 68.9 mg/L 
(strain P2121 with 0.01 mM IPTG). However, the highest titer (~68.9 mg/L) 
was much lower than that of the PGG02 (~200 mg/L), and the highest 
specific production (~12.0 mg/L/OD) was also lower than that of PGG02 
(~16.9 mg/L/OD). And a noteworthy phenomenon was that cell density 
decreased significantly when the inducer IPTG concentration was 0.03 
mM, which suggested cells were under stress when more IPTG was used. 
 
 
Figure 3-5. Optimization of AD production by controlling 4 modules. 
TM1, TM2 and TM3 promoters were used to control the expression of the four modules: 
galP-glk, dxs, ispDF-idi and ispA-ADS. The strains were named according to their 
sequence of promoters, e.g., P1271 refers to a construction in which the four modules 
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galP-glk, dxs, ispDF-idi and ispA-ADS are under the control of TM1, TM2, TM3 and TM1 
promoter, respectively. (A) AD titer (mg/L). (B) Cell density of different strains. (C) 
Specific yield of AD (mg/L/DO). (D) Illustration of different constructions (The thickness of 
arrows represents the relative strength of promoters). 
 
 
3.2.5 Regression analysis of modular controlling 
To identify the global optimal constructions and understand the behavior 
of the four-module-controlling system, a linear regression model was 
applied to the experimental data in Figure 3-5. The AD titers in all the 
different conditions were plotted based on the relative expression (Table 
3-1) of each module (Figure 3-6A). The relative expression of each 
module was calculated from the strength of promoters and copy numbers 
of plasmids, as described in materials and methods. For the ease of 
visualization and analyses, the data were shown as heat maps using a 
linear regression model (Figure 3-6B). Based on the calculations, the 
optimal ranges for the first (galP-glk) and second (dxs) modules were 
successfully covered by the 14 chosen constructions. However, for the 
third (ispDF-idi) and fourth (ispA-ADS) modules, the optimal conditions 
may not have been suitably covered in the collection of constructs. As 
shown in Figure 3-6B, the optimal ranges of relative expression levels for 
the four module ispDF-idi and ispA-ADS were 0.05~0.2, 0.2~0.4, below 
0.2 and above 0.4, respectively. A relatively low expression of first module 
(galP-glk) were beneficial to AD production. This was reasonable, 
because excessive expression of the first module inhibited cell growth and 
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very low expression was not sufficient to provide enough carbon sources 
thus decreased the final yield. Low expression level of the third module 
was beneficial to AD production. Further experiments indicated that the 
gene ispDF in the third module were less important (data not shown) and 
the overexpression of ispDF may overburden the cells. This could be due 
to the enzymes encoded by ispDF were more soluble [60] and possessed 
higher activities than the other rate-limiting steps thus this may require 
relatively lower expression levels. Higher expression levels for the second 
module and the fourth module were required. The expressed dxs gene in 
the second module was found to be less soluble than ispDF, and hence to 
achieve higher activity of dxs, a higher expression was required. The 
fourth module also required higher expression level as the activity of 
heterologous ADS from Artemisia annua is known to be poor in E. coli 
[126, 127]. Hence, a higher expression of this module was required. 
 
Table 3-2. Relative expression levels of each module in the 14 constructions 
# Strain 
Relative expression level of each module 
galP-glk dxs ispDF-idi ispA-ADS 
1 P1271 0.17 0.21 0.09 0.52 
2 P2271 0.08 0.24 0.10 0.58 
3 P7271 0.04 0.25 0.11 0.61 
4 P1772 0.31 0.16 0.16 0.37 
5 P2772 0.15 0.20 0.20 0.45 
6 P7772 0.07 0.22 0.22 0.50 
7 P1121 0.12 0.37 0.15 0.37 
8 P2121 0.05 0.39 0.16 0.39 
9 P7121 0.02 0.41 0.16 0.41 
10 P2111 0.04 0.32 0.32 0.32 
11 P7111 0.02 0.33 0.33 0.33 
12 P1717 0.20 0.10 0.59 0.10 
13 P2717 0.09 0.12 0.67 0.12 
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Figure 3-6. Regression and prediction of the optimal expression levels of the four 
modules. 
(A) AD titers (mg/L) versus different expression levels of each module. (B) Regression of 
AD titers (mg/L) on the relative expression levels of every two modules. Relative 
expression levels were calculated based on the promoter strength and plasmid copy 
number (described in Materials and Methods). 
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3.3 Discussion 
PEP synthase (ppsA) catalyzes pyruvate to PEP, and it has been used to 
enhance the production of lycopene (a C40 isoprenoids) [22, 23]. 
Consistent with the literature results, the AD production was predictably 
increased when ppsA was overexpressed (Figure 3-2). This inspired us to 
explore the productivity of the PTS knockout strain, as inactivating the 
PTS can potentially redirect PEP produced from glucose to the synthesis 
of downstream isoprenoids [32, 121]. In E. coli, the PTS is the main 
glucose transport system and is also responsible for carbon catabolite 
repression (CCR) and chemotaxis [90]. Thus deletion of the PTS is also 
pleiotropic and its mutant has several distinct characteristics over the wild 
type strain, such as enhancement of intracellular PEP concentration, 
coexistence of glycolytic and gluconeogenic pathway and the 
simultaneous utilization of different carbon sources [119]. The PTS mutant 
is able to co-utilize xylose and glucose [77] and produces higher titers of 
various compounds such as recombinant proteins [83], aromatics [32], 
lysine [84], L-phenylalanine [85] and succinate [86]. However, the uptake 
rate of glucose in PTS mutant is very slow and thus the mutant grows very 
slowly. Therefore, in this study, the GGS was overexpressed in the PTS 
deficient mutant to enhance the glucose transport.  
In line with our hypothesis that the production of AD was limited by the 
availability of PEP, the use of GGS (consuming ATP) for glucose uptake 
was more beneficial for AD production than that of the PTS (consuming 
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PEP) (Figure 3-3). However, it was observed that higher expression of the 
GGS improved specific yield of AD but inhibited cell growth in strain PGG 
and MGG (Figure 3-3). Therefore, a fine-tuning of the expression of the 
GGS was tested, as expected, this indeed improved the AD titer through 
improving the biomass. In addition, the specific production (mg/L/OD) was 
also improved by 38%, resulting in an increase in AD titer by more than 3 
fold (Figure 3-4).  
Production of taxadinene, an isoprenoid, has been shown to be 
significantly improved by balancing the DXP pathway and taxadiene 
synthesis pathway [13]. Considering the benefit of using the GGS glucose 
uptake pathway, we hypothesized that global pathway balancing of 
glucose uptake pathway, DXP pathway and AD synthesis pathway may 
further improve the production. Although the AD yield varied by more than 
190 fold in the panel of constructs and conditions, the maximal yield was 
69 mg/L (Figure 3-5) which was slightly higher than the yield when using 
PGG strain (60 mg/L) and significantly lower than PGG01 (182 mg/L) or 
PGG02 (201 mg/L). It is noteworthy that the cell density declined 
significantly when inducer dosage (IPTG concentration) was increased to 
0.03mM. The decreased cell density at high induction level is likely to be 
due to the stress of high expression of galactose permease and glucose 
kinase [120], the toxicity of accumulated high-concentration of glucose-6-
phosphate or inhibition from high concentration IPTG [90], and further 
study is required to address this issue. 
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To better understand the behavior of the four-module-controlling system, 
we analyzed the experimental data of the four-module system using a 
linear regression model. Based on the regression analysis (Figure 3-6), 
the optimal ranges of expression level for the first and second module 
were within the panel of constructs. However, none of the constructs 
managed to capture the optimal range of expression levels for the third 
and fourth modules. More importantly, combining the regression model of 
the fourth-module constructs with the results of PGG01, PGG02 and 
PGG03 in Figure 3-4 (in which ispDF were not overexpressed), we 
concluded that the ispDF in the second module was less important in 
contributing to AD production. Excluding ispDF from the system is 
beneficial to the system possibly because part of limited resources were 
wasted for producing ispDF. Furthermore, it was predicted in the 
regression model that relatively lower expression of galP-glk and higher 
expression of dxs and ispA-ADS were beneficial for AD production. And all 
of these predictions were just consistent with the expression levels in 
strain PGG01 (TI1-galP-glk, T7-dxs-T7-idi-ispA-ADS) and PTS02 (TI2-
galP-glk, T7-dxs-T7-idi-ispA-ADS). That explained the observation that 
PGG01 and PGG02 produced the higher titer of AD than all the chosen 
four-module-controlling constructs. 
3.4 Conclusion 
In this study, the increased availability of PEP was shown to be important 
in improving AD production via the DXP pathway. To increase intracellular 
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PEP concentration, the PEP-consuming PTS was replaced with the GGS 
that uses ATP for glucose uptake, consequently, this strategy increased 
AD titer by ~ 6 fold. Furthermore, fine tuning of the expression levels of the 
GGS further improved AD titer by another 3 fold by increasing the biomass 
and the specific yield. A global and systematic optimization was performed 
to simultaneously control the expression of glucose uptake pathway, DXP 
pathway and AD synthesis pathway. The optimal ranges for each module 
were analyzed and provided possible routes to improve the productivity of 
AD. 
3.5 Materials and Methods 
3.5.1 Bacteria strains and plasmids 
( FROL .0*ǻUHF$ǻHQG$'( was used as the parental strain 
[13]. 0* ǻ376)57 (PTS- for short) strain was obtained by 
replacing operon ptsHIcrr with a kanamycin-resistant gene using the Ȝ
Red recombination system [24]. And the kanamycin resistant gene was 
subsequently excised by the Flp/FRT site-specific recombination system 
[128]. Chromosomal deletions were verified by testing for antibiotic 
markers and colony PCR analysis. 
Plasmid pET-galP-glk was constructed from three parts, pETaa vector, 
gene galP and gene glk by Cross-lapping In Vitro Assembling (CLIVA) 
method using I-pETR(galPF), I-galPF(pETR), I-galPR(glkF), I-glkF(galPR), 
I-pETF(glkR) and I-glkR(pETR) (Table 3-2) [129]. Plasmids pETA-
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TM1/2/3-galP-glk were constructed from pET-galP-glk by mutating T7 
promoter to TM1/TM2/TM3 promoter using the oligo TM1, TM2 and TM3. 
Plasmid p15A-spec-T7-ppsA was constructed from two parts 15A-spec 
vector and ppsA gene by CLIVA method using I-ppsA(t7pr)-F, I-ppsA(t7tf)-
R, I-T7P(-)-R and I-T7T(-)-F (Table 3-2). Plasmid pBAD-galP-glk was 
constructed from pBAD-B (Invitrogen) and pET-galP-glk by CLIVA 
methods using I-gg-F(pBADR), I-gg-R(pBADF), I-pBAD-F(ggR) and I-
pBAD-R(ggF). 
All the information about the strains, plasmids and primers is in Table 3-2 
and Table 3-3. 
3.5.2 Media and culture conditions 
3.5.2.1 Defined media composition 
The defined media without carbon contained 4 g/L (NH4)2HPO4, 3.50 g/L 
KH2PO4 and 9.28 g/L K2HPO4, 1.7 g/L citric acid, 0.5 g/L MgSO4, 2.5 mg/L 
CoCl2·6H2O, 15.0 mg/L MnSO4·4H2O, 1.5 mg/L CuSO4·2H2O, 3 mg/L 
H3BO3, 2.5 mg/L Na2MoO4·2H2O, 13 mg/L Zn(CH3COO)2, 60 mg/L Fe(III) 
citrate and 8.4 mg/L EDTA. And 20 g/L glucose was added into the 
defined media before use.  
All the AD titers reported here were based on the strains grown in the 
defined media supplemented 20 g/L with glucose. 
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3.5.2.2 2xpy media composition 
The 2xpy media contained 20 g/L peptone, 10 g/L yeast extract and 10 g/L 
NaCl. The pH of the media was adjusted to 7.0 and the media was 
autoclaved at 121 °C for 20 mins. 
3.5.3 Culture conditions 
New transformed strains were rescued and grown in 2xpy media 
overnight, and 1% (v/v) overnight grown cell culture was inoculated into 1 
mL defined media in a 14mL BD Falcon™ tube. Two hundred microliter 
dodecane with 100 mg/L beta-caryophyllene was added on top of the 
culture. Cells were grown at 28°C with 300-rpm shaking speed, and 
induced with IPTG (for T7 or mutated T7 promoter) or L-arabinose (for 
araBAD promoter) when OD600 reached the range of 0.5~1.0. The media 
were selectively supplemented with 100 mg/L ampicillin, 34 mg/L 
chloramphenicol, 50 mg/L kanamycin and 100 mg/L spectinomycin to 
maintain the pET-11a derived plasmids, pAC-LYC derived plasmids, 
pETK-lacI and p15A-spec-T7-ppsA respectively. 
3.5.4 Quantification of AD 
Amopha-4,11-GLHQHZDV H[WUDFWHGE\GLOXWLQJȝ/GRGHFDQHShase into 
 ȝ/ HWK\O DFHWDWH DQG DQDO\]HG RQ DQ $JLOHQW $ JDV
chromatograph equipped with an Agilent 5975C mass spectrometer 
(GC/MS). Beta-caryophyllene (Sigma-Aldrich) was used as an equivalent 
and the GC-MS condition was essentially as the method reported [130]. 
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3.5.5 Calculation of relative expression of modules  
Relative expression level of each module was calculated based on the 















Where, Ei is the relative expression level of the module i in the 
construction C, Mi is the promoter strength of module i and the Ni is the 
plasmid copy number of module i. 
For example, the strengths of TM1, TM2 and TM3 were 92%, 37% and 
16% of that of T7 promoter, respectively; the first module was on the pAC 
vector (p15a origin) with around 10 copies, and the other three modules 
were on pET vector (pBR322 origin) with about 30 copies, respectively. 
Therefore, the relative expression level of the first module (galP-glk) in 
strain P1271 was 
1
92% 10(P1271) 0.17
92% 10 (37% 16% 92%) 30
E u  u    u  
 
Table 3-3. Strains, plasmids and primers used in this study 
Strains/Plasmids/Primers Description/sequence References 
Strains 
MG1655 DE3 E. coli .0*ǻUHF$ǻHQG$'( [13] 
0*'(ǻ376)57 0*'(GHULYHGǻSVW+,FUU)57 This study 
Plasmids 
p15A-spec-T7-ppsA 
pAC-LYC derived [131], replacing crtEBI with ppsA under the control 
of T7 promoter, and chloramphenicol resistant gene was replaced 
with spectinomycin  resistant gene. 
This study 
pETA-galP-glk pET-11a (Novagen) derived, galP-glk operon under the control of T7 promoter. This study 
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pETA-TM1-galP-glk pETA-galP-glk derived, mutating T7 promoter to TM1 promoter, which is 92% strength of T7 promoter. This study 
pETA-TM2-galP-glk pETA-galP-glk derived, mutating T7 promoter to TM2 promoter, which is 37% strength of T7 promoter. This study 
pETA-TM3-galP-glk pETA-galP-glk derived, mutating T7 promoter to TM3 promoter, which is 16% strength of T7 promoter. This study 
pBAD-galP-glk pBAD-B (Invitrogen) derived, galP-glk operon were put under the control araBAD promoter. This study 
pACM-T7-dxs-T7-ADS-ispA-
idi 
pAC-LYC derived, dxs-ADS-ispA-idi operon is under the control of 
T7 promoter. This study 
pETK-lacI pET-11a derived, ampicillin resistant gene was replaced with kanamycin resistant gene using CLIVA. This study 
pACM-TM2-dxs-TM3-idi-
ispDF-TM1-ADS 
pAC-LYC derived, dxs, idi-ispDF and ADS are under the control of 
TM2, TM3 and TM1 promoter, respectively. [RY] 
pACM-TM3-dxs-TM3-idi-
ispDF-TM2-ADS 
pAC-LYC derived, dxs, idi-ispDF and ADS are under the control of 
TM3, TM3 and TM2 promoter, respectively. [RY] 
pACM-TM1-dxs-TM2-idi-
ispDF-TM1-ADS 
pAC-LYC derived, dxs, idi-ispDF and ADS are under the control of 
TM1, TM2 and TM1 promoter, respectively. [RY] 
pACM-TM1-dxs-TM1-idi-
ispDF-TM1-ADS 
pAC-LYC derived, dxs, idi-ispDF and ADS are under the control of 
TM1, TM1 and TM1 promoter, respectively. [RY] 
pACM-TM3-dxs-TM1-idi-
ispDF-TM3-ADS 
pAC-LYC derived, dxs, idi-ispDF and ADS are under the control of 
TM3, TM1 and TM3 promoter, respectively. [RY] 
Primers 
TM1 promoter TAATACGACTCACTAATGGGGA This study 
TM2 promoter TAATACGACTCACTCGAGGGGA This study 
TM3 promoter TAATACGACTCACTATAGAAGA This study 
I-pETR(galPF) AGCGTCAGGCATA*TGTATATCTCCTTC*TTAAAGTT This study 
I-galPF(pETR) AAGGAGATATA*CATATGCCTGACGCT*AAAAAAC This study 
I-galPR(glkF) GATCTGCCTCCT*TTAATCGTGAGCG*CCTA This study 
I-glkF(galPR) CGCTCACGATTA*AAGGAGGCAGATC*AAATGACAAAGTATGCATTAGTC This study 
I-pETF(glkR) GGTCACATTCT*GTAAAAGCTGAGTTGGC*TGC This study 
I-glkR(pETR) GCCAACTCAGCTT*TTACAGAATGTGACC*TAAGG This study 
I-gg-F(pBADR) ATTAACCA*TGCCTG*ACGCTAAAAAAC This study 
I-gg-R(pBADF) AACAGCCT*TACAGA*ATGTGACCTAAGG This study 
I-pBAD-F(ggR) TCTGTAAG*GCTGTT*TTGGCGGATGAG This study 
I-pBAD-R(ggF) CAGGCATG*GTTAAT*TCCTCCTGTTAGCCC This study 
I-ppsA(t7pr)-F CCCTCTAGAA*ATAATTTTGTT*TTTCTCAAACCGTTCATTTA This study 
I-ppsA(t7tf)-R CCAACTCA*GCTTCCTTT*AACGCAGGATGTCTGTGAA This study 
I-T7P(-)-R AACAAAATTATT*TCTAGAGGG*GAA This study 
I-T7T(-)-F AAAGGAAG*CTGAGTTGG*CTG This study 
* The oligos asterisked are phosphorothioate-modified oligos used for CLIVA cloning [129]. 
 
Table 3-4. Name list for strains carrying different plasmids used in this study 
Strain Plasmid Short Name Reference 
MG1655 DE3 
ǻ376)57 pETA-galP-glk and pACM-T7-dxs-T7-ADS-ispA-idi PGG This study 
MG1655 DE3 pETA-galP-glk and pACM-T7-dxs-T7-ADS-ispA-idi MGG This study 
MG1655 DE3 pETK-lacI and pACM-T7-dxs-T7-ADS-ispA-idi MGG01 This study 
MG1655 DE3 p15A-spec-T7-ppsA, pETK-lacI and pACM-T7-dxs-T7-ADS-ispA-idi MGG02 This study 
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Chapter 4. STATISTICAL MEDIA OPTIMIZATION 
4.1 Introduction 
Optimization of growth medium is an effective method to increase cell density 
and production of recombinant proteins [132, 133] and bulk chemicals [134, 135]. 
However, growth medium optimization has not been systematically investigated 
in metabolic engineering of microbes for the production of isoprenoids. A variety 
of standard media are commonly used for isoprenoid production without major 
modifications, including both complex media (LB [19, 54], 2xYT [136, 137], TB 
[96, 138]) and defined media (M9 [19, 139], 2xM9 [16, 140]). In medium 
optimization, it is usually impractical to test the full combination of all the 
ingredients at different concentrations due to the relatively large number of 
possibilities. It is also a challenge to construct a mechanistic model to predict the 
optimal medium composition for the production of isoprenoids, due to the lack of 
understanding of the biological functions of each medium ingredient and their 
interactions. Statistical design of experiments to screen critical components and 
optimize the concentration of the screened components by response surface 
methodology (RSM) offers a unique opportunity to determine the optimal 
concentrations of these components in the media with the minimal number of 
experiments.  
In this study, the enhancement of lycopene production in E. coli was investigated 
by increasing the intracellular concentration of PEP using a PTS knocked out 
mutant. PTS knockout resulted in low cell growth in media containing only 
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glucose as the carbon source. In order to increase cell density, the growth 
medium was then systematically optimized with the aid of factorial experiment 
design. Both of cell growth and productivity of lycopene was enhanced by the 
medium optimization, the mechanism of which was subsequently investigated by 
metabolite and transcription profiling. In addition to the significant enhancement 
of lycopene production, amorpha-4,11-diene production was similarly enhanced 
by the use of the approach described herein, suggesting the approach has a 
broader utility for production of other isoprenoids. 
4.2 Results 
4.2.1 Increasing lycopene production and biomass of PTS mutant 
strain 
PEP is a glycolytic intermediate and a major phospho-donor for many cellular 
processes. PEP can be converted to phosphoglycerates and then to 
glyceraldehyde 3-phosphate (GAP), the limiting precursor of the DXP pathway 
(Figure 4-1) [23]. It is reasonable that isoprenoid production can be enhanced 
through increasing the supply of PEP by deleting selective competing pathways, 
such as the phosphotransferase system (PTS). To test this hypothesis, the 
ptsHIcrr operon (encoding the components of the PTS) in E. coli genome was 
deleted, and the production of lycopene, a C40 isoprenoid, was compared in both 
the wild-type strain (MG01) and the knockout strain (PTS01). In line with the 
hypothesis, lycopene yield (g/g DCW) was increased by about three fold in 
PTS01 as compared to MG01 (Figure 4-2). However, the cell density was 
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exceptionally low in the glucose minimal medium, consistent with previous 
reports [32]. This was likely due to the disruption of glucose uptake by PTS [38].  
 
 
Figure 4-1. Relationship of the central metabolic and DXP pathways 
The abbreviations for metabolites in the figure were as follows: glycerol (Gly), glucose (Glu), 
glucose-6-phosphate (G6P), glycerol-3-phosphate (G3P), dihydroxyacetone phosphate (DHAP), 
glyceraldehyde 3-phosphate (GAP), 1,3-biphospho-glycerate (G1,3P), 3-phospho-glycerate 
(3PG), 2-phospho-glycerate (2PG), phosphoenolpyruvate (PEP), the phosphotransferase system 
(PTS), pyruvate (PYR), oxaloacetate (OAA), tricarboxylic acid cycle (TCA), 1-deoxy-D-xylulose 5-
phosphate (DXP), 2C-methyl-D-erythritol 4-phosphate (MEP), 4-diphosphocytidyl-2C-methyl D-
erythritol (CDP-ME), 4-diphosphocytidyl-2C-methyl D-erythritol 2-phosphate (CDP-MEP), 2C-
methyl-D-erythritol 2,4-diphosphate (MEC), hydroxylmethylbutenyl diphosphate (HMBPP), 
isopentenyl diphosphate (IPP) and dimethylallyl diphosphate (DMAPP), farnesyl pyrophosphate 
(FPP), geranylgeranyl pyrophosphate (GGPP), phosphate (PPi), carbohydrate 
phosphotransferase system (PTS). The abbreviations for enzyme-coding genes in the figure are 
as follows: PTS enzyme IIBC (ptsG), histidine protein (ptsH), PTS enzyme I (ptsI), PTS enzyme 
IIA(crr), glycerol facilitator (glpF), glycerol kinase (glpK), glycerol-3-phosphate dehydrogenase 
(glpD), triose phosphate isomerase (tpi), glyceraldehyde-3-phosphate dehydrogenase A (gapA), 
phosphoglycerate kinase (pgk), phosphoglycero mutase III (gpmM), phosphoglyceromutase I 
(gpmA), enolase (eno), PEP carboxylase (ppc), PEP carboxykinase (pck), phosphoenolpyruvate 
synthetase (ppsA), pyruvate kinase type I and II (pykFA), DXP synthase (dxs), DXP reductase 
(dxr), CDPME synthase (ispD), CDPME kinase (ispE), CDPMEP synthase (ispF), HMBPP 
synthase (ispG), HMBPP reductase (ispH), IPP isomerase (idi), farnesyl pyrophosphate (FPP) 
synthase (ispA), GGPP synthase (crtE), phytoene synthase (crtB) and phytoene desaturase (crtI) 
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In order to improve the cell growth of PTS01, glycerol was added into the media 
to replace glucose. Cell density was found to increase with the addition of 
glycerol into the media, and the best growth was obtained when glycerol was 
used as the sole carbon source. More importantly, the specific productivity of 
lycopene (g lycopene / g DCW) in glycerol media was comparable to that of the 
media that had glucose as the sole carbon source. In addition, PTS01 produced 
more lycopene than MG01 in the glycerol media (Figure 4-2).  
 
 
Figure 4-2. Comparison of lycopene yield and cell density of MG01 and PTS01 strains grown in 
different media compositions 
Lycopene production and OD were assayed after 24 h for MG01 and PTS01 strains grown in 
Riesenberg media [141] containing different concentrations of glucose and glycerol. The carbon 
concentrations in media A, B, C, D were 10 g/L glucose + 0g/L glycerol, 7 g/L glucose + 3 g/L 
glycerol, 3 g/L glucose + 7 g/L glycerol and 0 g/L glucose + 10 g/L glycerol, respectively. All other 
components in the Riesenberg media were the same. The strains grew in the media at 37°C and 
225 rpm). 
 
4.2.2 Statistical optimization of growth media  
A systematic optimization of the growth medium for PTS01 was performed to 
increase lycopene productivity. The contributions of five ingredients to lycopene 
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productivity were characterized using a minimal run resolution IV fractional 
factorial design (Table 4-1 and Table 4-2), based on the glycerol minimal medium 
optimized for high cell density [142]. The five factors chosen for optimization are: 
Glycerol, KH2PO4, (NH4)2HPO4, sodium pyruvate, and L-arabinose. Glycerol was 
the major carbon source in media; KH2PO4 served as a buffer, ionic agent and 
phosphorus source; (NH4)2HPO4 was the source of both nitrogen and 
phosphorus; sodium pyruvate was used as the substrate of the DXP pathway for 
lycopene production; and L-arabinose was used to induce the pBAD vector for 
the expression of dxs-idi-ispDF operon. 
 
Table 4-1. Summary of selected medium ingredients for screening (Details of experiment design 
are shown in Table S1 in File S1). 
Factor Name Unit Low (-) High (+) Function in media 
A Glycerol g/L 8 20 C source 
B KH2PO4 g/L 8 20 P source, buffer 
C (NH4)2HPO4 g/L 2 5 N source, buffer 
D Na(Pyruvate) g/L 2 5 Precursor 
E L-Arabinose mM 0 0.1 Inducer 
 
Table 4-2. Experimental design of Min Run Res IV for the production of lycopene of PTS01 strain 
No. Glycerol KH2PO4 (NH4)2HPO4 Pyruvate Inducer Lycopene 
Unit g/L g/L g/L g/L mM µg/g DCW 
1 8 8 5 5 0 1992 
2 8 8 5 2 0 1755 
3 20 8 2 2 0 2705 
4 8 20 5 5 0.1 4688 
5 20 8 5 5 0 4694 
6 20 20 2 2 0.1 7304 
7 20 8 5 2 0.1 4337 
8 8 20 2 5 0 4851 
9 20 20 5 2 0 6473 
10 8 20 2 2 0.1 5444 
11 8 8 2 5 0.1 3578 
12 20 20 2 5 0.1 7568 
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The results of experimental design showed that glycerol and KH2PO4 were the 
most important factors for lycopene production (Figure 4-3A) and the 
relationships can be described by Equation 3-1 (Factor A is glycerol and factor B 
is KH2PO4). The equation indicated that lycopene production was enhanced by 
increased concentrations of glycerol and KH2PO4. 
836 150* 240*Lycopene A B              Equation 4-1 
After identifying the two critical ingredients in media for lycopene production, the 
optimal concentrations were further determined by applying RSM with a central 
composite design (Table 4-3). The experimental results were analyzed 
statistically using ANOVA. The mean predicted and observed responses, and the 
details of the statistical analysis, are presented in Table 4-3 and Table 4-4. The 
values of the regression coefficients were calculated and the fitted equation (in 
terms of coded values) for the prediction of lycopene production (µg/g DCW) are 
shown in Equation 3-2, where Factor A is glycerol and factor B is KH2PO4. 
2 211944 2524* 35* 1216* * 496* 2795*Lycopene A B A B A B      Equation 4-2 
 
Table 4-3. Central composite design of RSM design for production of lycopene of PTS01 strain 
with corresponding results 
Order Glycerol/ (g/L) KH2PO4/ (g/L) Observed  / (µg/g DCW) Predicted / (µg/g DCW) 
1 10 20 5602 4947 
2 30 20 11365 12429 
3 10 50 8184 7308 
4 30 50 9083 9925 
5 5.9 35 6258 7380 
6 34.1 35 15831 14522 
7 20 13.8 6654 6404 
8 20 56.2 6240 6303 
9 20 35 13331 12222 
10 20 35 12142 12222 
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11 20 35 12107 12222 
12 20 35 11733 12222 
13 20 35 11797 12222 
 
Based on this equation, optimal concentrations of glycerol and KH2PO4 for 
production of lycopene (16,261 µg/g DCW) were predicted to be 50 g/L and 24 
g/L, respectively (Figure 4-3B). To verify the model, lycopene production was 
measured from E. coli grown in these predicted optimal concentrations of 
glycerol and KH2PO4. The measured lycopene yield was 17542±1105 µg/g DCW 
(Table 4-5), similar to the predicted optimized yield of 16,261 µg/g DCW, thereby 
validating the model.  
 
 
Figure 4-3. Identification and optimization of critical media composition for the production of 
lycopene in PTS01 strain. 
(A) Half-normal probability plot of the results of minimal resolution IV experiment design (The 
details of the experiment design were shown in Table S1 in File S1). In the half-normal probability 
plot, the line was called the near zero line. The estimated effect of an unimportant factor will 
typically be on or close to a near-zero line, while the estimated effect of an important factor will 
typically be displaced well off the line. (B) RSM plot of lycopene production versus concentrations 
of glycerol and KH2PO4 of PTS01. 
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Source Coefficient Estimate p-value 
Model  0.001 
A-Glycerol 2525 0.0003 
B-KH2P04 -36 0.9261 
A*B -1216 0.0540 
A2 -635 0.1551 
B2 -2934 0.0002 
 
Table 4-5. Model prediction and experimental validation of RSM 
Item Glycerol (g/L) KH2PO4 (g/L) Lycopene (ppm) 
Model Prediction 50 24 16261 
Verifying Experiment 50 25 17542±1105 
R-Squared 0.95   
Adj R-Squared 0.90   
 
As shown in Figure 4-4A, PTS01 grown in this optimized media (designated 
OPT1) produced more than twice as much lycopene as MG01. PEP 
concentrations were consistently higher in PTS01 than MG01 at all growth phase 
(Figure 4-4B). There is a correlation between lycopene production and PEP 
concentration, suggesting that increased lycopene production can be attributed 
to higher amounts of PEP available.  
 
Figure 4-4. Comparison of lycopene production, growth curve and PEP levels of MG01 and 
PTS01 
(A) Growth curve and lycopene productions of PTS01 and MG01 in optimal glycerol medium 
(OPT1) at 37°C, with a shaking speed of 300 rpm. (B) Comparison of PEP levels in MG01 and 
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induction; stationary phase, 36 h post-induction). Both of the strains were grown in OPT1 at 37°C, 
with a shaking speed of 300 rpm). 
 
The culture conditions of temperature and O2 feeding (controlled by rotation 
speed of incubation) were optimized. It was found that by increasing rotation 
speed to 300 rpm from 225 rpm, and keeping culture temperature at 37°C (earlier 
experiments were conducted at 225 rpm and 37°C), lycopene yield was 
increased to around 20,000 µg/g DCW for PTS01 (Figure 4-5A).  
The optimized medium (OPT1) and culture conditions were used in further 
experiments to investigate the effect of PTS deletion on the accumulation of 
intracellular PEP and the concomitant increase in lycopene productivity. 
The growth rate and lycopene productivity of cells grown in OPT1 were 
compared with other commonly used complex medium (2xPY, LB, 2xYT) and 
defined medium (2xM9 with 10 g/L glycerol, R-media with 10 g/L glycerol). It was 
found that the optimized medium, OPT1, was superior in lycopene production 
(Figure 4-5B) compared to all other media tested. Although the strain grew faster 
in complex media (LB, 2xYT and 2xPY), the biomass yields were lower when 
compared to the defined media, including OPT1 (Figure 4-5C). By using this 
approach to optimize lycopene production using the DXP pathway, we achieved 
the highest lycopene yield reported so far, compared to previous studies [16, 
143].  
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Figure 4-5. Optimization of culture conditions for PTS01 and comparison of OPT1 with other 
commonly used media. 
(A) Lycopene production of PTS01 at different temperatures and shaking speeds. (B) 
Comparison of lycopene production of PTS01 in 2xPY, LB, 2xYT, 2xM9, R-media and OPT1 
media. The strain was grown at 37°C, with a shaking speed of 300 rpm. (C) The growth curves of 
PTS01 in 2xPY, LB, 2xYT, 2xM9, R-media and OPT1 media. 
 
Table 4-6. Reported lycopene titer in literature 
# Lycopene titer Lycopene yield Productivity Media Host Literature 
Unit mg/L ppm mg/L/h 
   
1 775 64900 8.1 
 
Blakeslea 
trispora Choudhari, S. M., et al. (2008). 
2 260 5400 4.333 2YT+gly Escherichia coli Kim, S.-W., et al. (2009) 
3 79 33430 
 
2YT+gly Escherichia coli Chen, Y. Y., et al. (2013) 
4 102 22000 
 





2XM9+glc Escherichia coli Alper, H., et al. (2005) 
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6 80 20,000 1.7 Def+gly Escherichia coli Zhang, C., et al. (2013) 
7 198 
  
2YT+gly Escherichia coli Rad, S. A., et al. (2012) 
8 220 27,000 8.8 2XM9+glc Escherichia coli Alper, H., et al. (2006) 
9 1350 32,000 33.8 AA+Def+gly Escherichia coli Kim, Y. S., et al. (2011) 
10 1480 30,300 32.2 Def+glc Escherichia coli This study 





F. E., et al. 
(2008) 
12 74 4,600 1.8 
 











rubrum Wang, G. S., et al. (2012). 
 
4.2.3 Transcriptional investigation and metabolites profiling of PST01 
grown in OPT1 medium 
Transcriptional analysis by qPCR has been used to gain mechanistic insights into 
metabolic engineering [85, 144]. The transcription of the genes involved in 
lycopene biosynthesis was investigated in order to better understand the 
underlying mechanisms affecting lycopene production in the OPT1 medium, and 
how it compares to complex media. The PTS01 strain harbored two plasmids 
(pBAD-SIDF and pAC-LYC) which overexpressed four rate-limiting genes of the 
DXP pathway (dxs, idi and ispDF) and three heterologous lycopene synthetic 
genes (crtE, crtB and crtI), respectively (Figure 4-1).  
PTS01 grown in complex media (2xPY) and the OPT1 medium was measured 
and compared using the expression level of one gene from each plasmid (dxs 
and crtE) and an endogenous DXP pathway gene (ispE). Interestingly, at 
different growth phases, the transcriptional levels of the plasmid-encoded genes 
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(dxs and crtE) were found to be up-regulated by approximately 4-8 times in the 
OPT1 medium, compared to those in 2xPY (Figure 4-6). Similarly, the plasmid 
copy numbers of both of these plasmids were up-regulated in the OPT1 medium 
(Figure 4-7). However, the expression level of the endogenous gene (ispE) was 
similar in both strains when grown in either media (Figure 4-6). These results 
indicate that increased transcriptions of dxs and crtE were probably due to the 
increase in plasmid copy number. Therefore, it was hypothesized that the OPT1 
medium increased the plasmid copy numbers of pBAD-SIDF and pAC-LYC in 
greater quantities than the 2xPY medium, and this led to the increased 
expression levels of the genes in those plasmids, and finally contributed to the 
increased production of lycopene. 
  
  
Figure 4-6. Fold change of transcriptional levels of dxs, ispE and crtE in PTS01 strain grown in 
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The transcriptional levels measured in 2xPY and OPT1 were compared at four different growth 
stages, late lag phase (0h for 2xPY and 0h for OPT1, the time of induction was set as time 0h), 
early log phase (2h for 2xPY and 4h for OPT1), middle log phase (4h for 2xPY and 10h for OPT1) 
and late log phase (4h for 2xPY and 10h for OPT1). The sampling time in each growth stage was 
due to differences in growth rates of PTS01 which was faster in 2xPY than in OPT1 (As shown in 
Figure 4-5C). All the measurements were normalized to the expression of cysG. 
 
  
Figure 4-7. Fold change of plasmid copy number in PTS01 grown in OPT1 and 2xPY media.  
The x-axis described parameters identical to Figure 4-6. Plasmid copy number was calculated 
using copy number of plasmid resistant gene (ampicillin resistant gene for pBAD-SIDF and 
chloramphenicol resistant gene for pAC-LYC) normalized by the copy number of chromosomal 
gene ispE.  
 
To test the hypothesis that co-upregulations of these genes were major 
contributors to the enhancement of lycopene production in the OPT1 medium, 
both the operon dxs-idi-ispDF and the operon crtEBI were overexpressed in 
2xPY. Using the pBAD vector, the operon dxs-idi-ispDF was put under the 
control of the araBAD promoter. The lycopene biosynthetic genes (crtEBI) were 
placed under the control of the araBAD promoter in the pAC vector (designated 
pACM-LYC, which was constructed from plasmid pAC-LYC by replacing the 
constitutive promoter with the araBAD inducible promoter). PTS02, a MG1655 
PTS- strain carrying pACM-LYC and pBAD-SIDF was then generated and grown 
in 2xPY media. By gradually increasing the concentration of L-arabinose, the 
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than or similar to that found in PTS01 in the OPT1 medium (Figure 4-8). 
Lycopene production was found to increase gradually from 500 to 6000 µg/g 
DCW with increasing amounts of L-arabinose, indicative of the enhancement of 
lycopene production by the co-upregulation of dxs-idi-ispDF and crtEBI. 
However, despite achieving transcriptional levels of dxs-idi-ispDF and crtEBI of 
PTS02 (grown in 2xPY) that were higher or at least comparable with those of 
PTS01 (grown in OPT1 medium), the maximal lycopene production of PTS02 in 
2xPY (~6000 µg/g DCW) was nonetheless found to be significantly lower than 
that of PTS01 in OPT1 (~18,000 µg/g DCW) (Figure 4-8). These results indicated 
that the co-upregulation of dxs-idi-ispDF and crtEBI was essential but not 
sufficient to enhance lycopene production to the levels observed in PTS01 grown 
in the OPT1 medium.  
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Figure 4-8. Transcriptional analysis of dxs, idi, ispD ispF, crtE, crtB and crtI. 
PTS02 was grown in 2xPY and induced with different concentrations of L-arabinose (0.1, 1 and 
10 mM). Columns labelled “C” represent the expression levels of PTS01 grown in OPT1 in the 
absence of the inducer (L-arabinose). Fold changes of transcriptional levels of these genes were 
normalized to the expression levels of corresponding genes of PTS01 grown in 2xPY in the 
absence of the inducer (L-arabinose). 
 
In addition to transcriptional analysis, metabolite profiling also provides useful 
information in attempts to understand underlying biochemical mechanisms [145]. 
The intracellular metabolites of the PTS01 cells grown in the 2xPY and OPT1 
media were profiled and compared. A panel of metabolites were found to be 
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glycerol-3-phosphate (G3P), DXP and pyrophosphate (Figure 4-9). G3P and 
DXP are critical intermediates in the isoprenoid synthetic pathway when routing 
from glycerol (the carbon source of the defined medium), and the increases in 
exponential state concentrations were consistent with enhanced lycopene 
production. The upregulated level of pyrophosphate was also expected in the 
OPT1 medium, as the medium contained large amounts of phosphate. Major 
cellular co-factors ATP and NADH were detected in different growth stages and 
most of their concentrations were comparable in the 2xPY and OPT1 media, 
suggesting that the increase in lycopene production was not due to changes in 





































































STATISTICAL MEDIA OPTIMIZATION 
Page 75 | 196 
 
 
Figure 4-9. Concentrations of metabolites and cofactors in PTS01 strain grown in 2xPY or OPT1 
media.  
The metabolites in 2xPY and OPT1 were compared at three different growth stages, early log 
phase (3h for 2xPY, 6h for OPT1) , middle log phase (6h for 2xPY, 12h for OPT1) and early 
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4.2.4 Production of amorpha-4,11-diene in PTS03 strain in 
defined media 
Using PTS deletion and media development, we have established a rapid 
and effective method to increase lycopene production in E. coli. In order to 
demonstrate the broader utility of this approach, the production of 
amorpha-4,11-diene, a distinct C15 isoprenoid, was attempted. The 
growth medium was optimized using the same statistical method as 
described before, where three important factors A, B and E (which are 
glycerol, KH2PO4 and L-arabinose, respectively) were screened by 
fractional factorial design (Figure 4-10A and Table 4-6). The optimal 
concentrations of the three critical factors were determined by RSM, and 
the results are shown in Figure 4-10B, Figure 4-10C and Table 4-7. This 
optimized medium for amorpha-4,11-diene was designated OPT2 and an 
enhancement of amorpha-4,11-diene production was observed (182 
mg/L), which was significantly higher than the yield derived from 2xPY 
complex media (35.3 mg/L). Similarly to lycopene, the production of 
amorpha-4,11-diene (182 mg/L) was better in the PTS- strain (PTS03) 
than in the wide type (MG02) in OPT2 medium (136 mg/L, Figure 4-10D). 
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Figure 4-10. Media optimization of amorpha-4,11-diene production in PTS03 strain.  
(A) Screening of key factors for amorpha-4,11-diene production (The factors share the 
same denotations as those described in Figure 4-3A.In the figure, A, B and E are 
dominant factors with positive effects on the production of amorpha-1.4-diene, therefore 
they were selected as key factors for further optimization). (B) Production of amorpha-
4,11-diene versus glycerol concentration and inducer dosage. (C) Production of 
amorpha-4,11-diene versus KH2PO4 concentration and inducer dosage. (D) Comparison 
of amorpha-4,11-diene production in 2xPY and OPT2 media for the MG02 and PTS03 
strains. The details of the experiment design are described in Supplementary Table 4-6 
and Table 4-7. 
 
Table 4-7. Experimental design of Min Run Res IV for the production of amorpha-4,11-













8 8 5 5 0.1 33.6 
8 8 5 2 0.1 26.3 
20 8 2 2 0.1 19.6 
8 20 5 5 0.3 40.4 
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20 20 2 2 0.3 69.2 
20 8 5 2 0.3 40.4 
8 20 2 5 0.1 46.3 
20 20 5 2 0.1 49.5 
8 20 2 2 0.3 52.1 
8 8 2 5 0.3 38.4 
20 20 2 5 0.3 55.0 
 
Table 4-8. Central composite design of RSM design for the production of 










Predicted AD / 
(mg/L) 
1 27.5 27.5 2 118.9 115.92 
2 35 35 3 158.9 147.25 
3 27.5 14.9 2 101.7 100.64 
4 35 20 3 139.0 136.4 
5 35 35 1 102.2 105.72 
6 27.5 27.5 2 98.5 115.92 
7 20 20 1 90.0 99.56 
8 27.5 27.5 3.7 111.3 126.64 
9 35 20 1 92.8 94.87 
10 27.5 27.5 2 118.9 115.92 
11 40.1 27.5 2 140.2 143.03 
12 27.5 40.1 2 107.8 115.85 
13 20 20 3 122.8 111.46 
14 20 35 3 122.8 118.7 
15 20 35 1 112.1 106.79 
16 27.5 27.5 2 119.1 115.92 
17 14.9 27.5 2 118.7 122.97 
18 27.5 27.5 2 121.6 115.92 
19 27.5 27.5 2 119.6 115.92 
20 27.5 27.5 0.3 90.0 81.71 
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4.3 Discussion 
In this study, the deletion of PTS and the use of statistical medium 
optimization enhanced the production of a C40 isoprenoid (lycopene) and 
a C15 isoprenoid (amorpha-4,11-diene), suggesting that the approaches 
developed herein may be used for optimizing the production of other 
isoprenoids. 
Increasing intracellular concentration of PEP in PTS knockout mutant 
when grown in glucose media has been reported to enhance the yield of 
aromatics [32, 38]. However, it is not known if PTS deletion can also 
enrich intracellular PEP when cells are grown in glycerol media. Glycerol 
uptake genes (glpF, glpK and glpD) are known to be regulated by carbon 
catabolite repression in E. coli and are intimately linked to Enzyme IIA 
(gene ccr,  part of the ptsHIcrr operon) and the ratio of PEP to pyruvate 
[81, 146, 147]. Although it is expected that PTS deletion will affect 
transcription of PTS related genes (e.g. pck, ppc, ppsA, pykFA and eno,  
Figure 4-1), no significant difference was found in the expression levels of 
these PEP related genes in PTS01 and MG01 (Figure 4-11). This does 
not rule out the possibility that PTS disruption may modulate post-
translational events resulting in PEP accumulation, an interesting 
possibility yet to be examined. PEP is thought to transfer phosphate to EI 
(gene ptsI), a PEP-dependent protein-kinase. The phosphate group is 
subsequently transferred from EI~P to HPr (gene ptsH), from HPr~P to the 
soluble EIIAGlc (sometimes also called EIIACrr), and finally from 
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EIIAGlc~P to the glucose-specific membrane protein EIICBGlc (gene 
ptsG), resulting in the uptake and phosphorylation of glucose (Figure 4-1) 
[81]. As there are more than 20 different Enzymes II in E. coli [148], the 
deletion of the ptsHIcrr operon in this study may cause a decrease in 
phosphorylation of these enzymes resulting in the accumulation of PEP. 
This hypothesis is the subject of future investigations. 
 
 
Figure 4-11. Fold change of transcriptional levels of genes involved in the metabolic 
pathway of glycerol in PTS01 and MG01 grown in OPT1 media. 
The growth media used in this study was OPT1 and all the samples of MG01 and PTS01 
were collected at early log phase. The expression levels of all the genes were normalized 
to cysG. 
 
PTS knockout not only affects the uptake of glucose but also plays an 
important role in carbon catabolite repression. This is because 
phosphorylated EIIAGlc binds and activates adenylate cyclase (AC), which 
leads to cyclic AMP (cAMP) synthesis, and high cAMP concentrations 
trigger the formation of cAMP–CRP (cyclic AMP (cAMP) receptor protein; 
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and activate the promoters of many catabolic genes [81]. It was also 
reported that the araBAD promoter was affected by CAP [149]. To 
understand the effects of PTS knockout on the activities of the araBAD 
promoter in the pBAD-SIDF and a constitutive promoter in pAC-crtEBI, the 
expression levels of genes in the pBAD-SIDF plasmid and pAC-crtEBI 
plasmid for the MG01 strain and PTS01 strain, both cultivated in OPT1 
media, were compared. However, the results indicated that the expression 
levels of all the genes in the two plasmids were not affected significantly 
when PTS was deleted (Figure 4-12). This could be because there was no 
arabinose added into the system, so the activity of the araBAD promoter 
was relatively low under such conditions and the effects of a PTS 
knockout was insignificant. 
 
 
Figure 4-12. Fold change of transcriptional levels of genes in the pBAD-SIDF and pAC-
crtEBI in PTS01 and MG01 grown in OPT1 media. 
The growth media used in this study was OPT1 and all the samples of MG01 and PTS01 
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The optimization of a growth medium is an effective method to increase 
cell density and production of recombinant proteins [132, 133] and bulk 
chemicals [134, 135]. To optimize the media, it was impractical to test the 
full combinations of components at different concentrations. Furthermore, 
it is a challenge to construct a mechanistic model to predict the 
interactions of the medium compositions with respect to the production of 
isoprenoids. Instead, we explored the use of statistically designed 
experiments [150] to screen critical components and optimize the 
concentrations rapidly, with a minimal number of experiments. From such 
studies, glycerol and KH2PO4 were identified as the most dominant factors 
in lycopene production, while pyruvate, (NH4)2HPO4 and inducer dosage 
were found to be less critical. The KH2PO4 was further validated by single-
factor experiment (Figure 4-13). It is likely that glycerol and KH2PO4 have 
global metabolic effects. Limiting the nitrogen supply increased the 
production of amorpha-4,11-diene [130], which is consistent with our 
results that (NH4)2HPO4 is not critical for the production of both lycopene 
and amorpha-4,11-diene. Pyruvate was determined to be less critical to 
the production of such isoprenoids, perhaps because of an abundance of 
intracellular pyruvate.  
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Figure 4-13. The effect of KH2PO4 concentration on lycopene production. 
The concentration of KH2PO4 in K1, K2, K3, K4 and R-media were 73, 173.5, 273.5, 
473.5 and 97.7 mM, respectively. All the other all the other components were kept at the 
same levels as the R-media. 
 
Interestingly, the effects of inducer dosage were different for the 
production of lycopene and amorpha-4,11-diene. For lycopene, low 
inducer dosage did not affect production and higher inducer dosage was 
detrimental to production in PTS01 (Figure 4-14). While there was an 
optimal inducer dosage for amorpha-4,11-diene production, too much or 
too little inducer had a negative impact. In addition to media composition, 
temperature and oxygen supply are also important factors that were tuned 
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Figure 4-14. The effect of Inducer dosage on lycopene production in the OPT1 media 
 
Our transcriptional analysis provided useful insights into how optimization 
of media resulted in increased lycopene production. The increase in dxs 
and crtE expressions was observed in OPT1 when compared to 2xPY 
(Figure 4-6). Further investigation indicated that the up-regulation of these 
genes was due to greater plasmid copy numbers in OPT1 (Figure 4-7). It 
is known that media composition can affect the quality and yield of 
plasmids [151]. Similarly, the alteration of carbon-to-nitrogen (C:N) ratio 
[152] and amino acid starvation [153] have also been shown to increase 
plasmid copy numbers. By lowering the specific growth rate, plasmid DNA 
yields can be increased [141]. This inverse correlation between plasmid 
DNA synthesis and growth rate was thought to be due to higher plasmid 
stability as well as increased plasmid replication in reduced growth rates 
[154]. The PTS deleted strain (PTS01) grew slowly in the OPT1 medium, 
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mechanisms to increase the plasmid copy number, thereby increasing 
transcription.  
Although lycopene production levels increased significantly, paralleling an 
increase in the transcription of dxs-idi-ispDF and crtEBI in 2xPY, the 
highest lycopene yield from 2xPY was still much less than in OPT1. These 
results suggest that the co-upregulation of dxs-idi-ispDF and crtEBI was 
required to enhance lycopene production, but was still insufficient to reach 
the levels observed in PTS01 grown in an OPT1 medium. Metabolite 
profiling results showed that major cellular co-factors ATP and NADH 
were comparable in the 2xPY and OPT1 media, suggesting that the 
availability of cofactors was unlikely to be a limitation and may not account 
for the increase in lycopene production in the OPT1 medium. In addition to 
the transcriptional upregulation of crtEBI, the prolonged exponential phase 
of OPT1 could be beneficial in diverting more carbon fluxes into DXP 
pathway, thus increasing the overall yield. 
4.4 Conclusion 
To our knowledge, this is the first study that demonstrated the 
enhancement of isoprenoid production (lycopene and amorpha-4,11-
diene) using the phosphotransferase system deficient strain of E. coli. The 
growth medium was rapidly optimized for the knockout mutant with the aid 
of statistical experiment design. This concurrently overcome cell growth 
retardation, a side effect of PTS disruption on a glucose medium, and 
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increased the production of lycopene, a C40 isoprenoid. The highest 
lycopene yield in this study was 20,000 µg/g DCW, which was a significant 
yield as compared to published reports. An attempt to understand the 
underlying mechanisms in cells grown in the optimized defined media 
demonstrated that the transcription of the lycopene biosynthetic genes 
was essential but insufficient to account for the observed enhancements in 
lycopene production. Deletion of PTS in combination with statistical 
medium optimization was also successfully applied to enhance the 
production of amorpha-4,11-diene, a distinct C15 isoprenoid, suggesting 
that the approach developed herein has broad utility beyond the scope of 
this study.  
4.5 Materials and methods 
4.5.1 Statistical experimental design 
Fractional factorial designs of experiment and response surface 
methodology were calculated using Design Expert® V8 Software, Stat-
Ease, Inc.  
4.5.2 Bacteria strains and plasmids 
E coli. K-12 MG1655 [F- lambda- ilvG- rfb-50 rph-1] was used as the 
parental strain, and MG1655 PTS- (PTS- for short) was used in the 
following experiments for lycopene production with the pAC-LYC plasmid 
[131]. PTS- strain was obtained by replacing operon ptsHIcrr with a 
kanamycin-resistant gene using the Ȝ Red recombination system 
STATISTICAL MEDIA OPTIMIZATION 
Page 87 | 196 
 
developed by Datsenko et al. [128]. The details of the oligos (EcoRB-
PTSF-KanF and EcoRBR-PTSR-KanR) and the plasmid pKD46 used for 
this work was shown in Table S6 in File S1, and the correct mutant of 
PTS- was verified by PCR with the wild-type strain as the control. Plasmid 
pBAD-SIDF was constructed via ligation of dxs-idi-ispDF operon amplified 
by polymerase chain reaction (PCR) from p20T7MEP [13] into a modified 
pBAD-B vector (Invitrogen), which controlled the expression of the dxs-idi-
ispDF operon using the araBAD promoter. Plasmid pACM-LYC was 
constructed by modifying the pAC-LYC plasmid so that three genes crtE, 
crtB and crtI were under the control of the araBAD promoter. Plasmid 
pAC-ADS was constructed based on pAC-LYC by replacing the crtEBI 
operon with the amorpha-4,11-diene synthase gene (ADS) using the 
ligase-independent cloning (LIC) method [155]. All the information about 
the strains, plasmids and primers is in Table S6 in File S1.  
4.5.3 Culture media and growth conditions 
1. Defined media recipe for optimization 
Different concentrations of glycerol, (NH4)2HPO4, KH2PO4, sodium 
pyruvate and citric acid were added into the media according to the 
experimental design. In addition, the media also contained 0.5 g/L MgSO4, 
2.5 mg/L CoCl2·6H2O, 15.0 mg/L MnSO4·4H2O, 1.5 mg/L CuSO4·2H2O, 3 
mg/L H3BO3, 2.5 mg/L Na2MoO4·2H2O, 13 mg/L Zn(CH3COO)2, 60 mg/L 
Fe(III) citrate, 4.5 mg/L thiamine·HCl and 8.4 mg/L EDTA.  
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The final optimized defined media for PTS01 consisted of 50 g/L Glycerol, 
24 g/L KH2PO4, 4 g/L (NH4)2HPO4, 1.7 g/L citric acid, and all the other 
components were kept at the same levels as the Riesenberg media [142]. 
This optimized defined medium was named OPT1.  
The final optimized defined media for PTS03 consisted of 45 g/L Glycerol, 
27.5 g/L KH2PO4, 4 g/L (NH4)2HPO4, 1.7 g/L citric acid, and all the other 
components were the same as the Riesenberg media [142]. This 
optimized defined medium was named OPT2. The concentration of L-
arabinose (inducer) in OPT2 was 5mM.  
All the defined media were adjusted to pH7.0 using a NaOH solution, and 
filtered with a 0.2 micron membrane. 
2. Riesenberg media (R-media) composition [142] 
The R-media contained 10 g/L glycerol, 4 g/L (NH4)2HPO4, 13.3 g/L 
KH2PO4 ,1.7 g/L citric acid, 2.5 mg/L CoCl2·6H2O ,15.0 mg/L MnSO4·4H2O, 
1.5 mg/L CuSO4·2H2O, 3 mg/L H3BO3, 2.5 mg/L Na2MoO4·2H2O, 13 mg/L 
Zn(CH3COO)2, 60 mg/L Fe(III) citrate, 4.5 mg/L thiamine·HCl and 8.4 
mg/L EDTA. 
Glycerol, (NH4)2HPO4, KH2PO4 and citric acid were autoclaved 
separately. Sterile solutions of glucose, MgSO4, and thiamine-HCl were 
added afterwards, the pH of the media was adjusted to 7.0, and the media 
was autoclaved at 121 °C for 20 mins. 
3. 2xM9 defined media composition [16] 
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The 2xM9 media contained 25.6 g/L Na2HPO4·7H2O, 6 g/L KH2PO4, 1 
g/L NaCl, 2 g/L NH4Cl , 2 mM MgSO4, 0.1 mM CaCl2 and 10 g/L glycerol. 
The pH of the media was adjusted to 7.0, and the media was autoclaved 
at 121 °C for 20 mins. 
4. 2xPY, LB and 2xYT complex media compositions 
The 2xPY media contained 20 g/L peptone, 10 g/L yeast extract and 10 
g/L NaCl. The pH of the media was adjusted to 7.0 and the media was 
autoclaved at 121 °C for 20 mins. 
The LB media contained 10 g/L tryptone, 5 g/L yeast extract and 10 g/L 
NaCl. The pH of the media was adjusted to 7.0 and the media was 
autoclaved at 121 °C for 20 mins. 
The 2xYT media contained 16 g/L tryptone, 10 g/L yeast extract and 5 g/L 
NaCl. The pH of the media was adjusted to 7.0 and the media was 
autoclaved at 121 °C for 20 mins. 
1% (v/v) overnight grown cell culture was inoculated into 1mL 2xPY or 
defined medium in a 14mL BD Falcon™ tube. Cells were grown at 37°C 
(or 28°C) with 300 rpm (or 225 rpm) shaking, and induced with L-
arabinose when OD600 reached the range of 0.5~1.0. The media were 
supplemented with 100 mg/L Ampicillin and 34 mg/L chloramphenicol to 
maintain the plasmids pBAD-SIDF and pAC-LYC (or pBAD-LYC) 
respectively. Besides, 25 mg/L kanamycin was added into the PTS01, 
PTS02 and PTS03 strain. For the strain that was producing amorpha-
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4,11-diene, the cells were grown at 28 °C in order to decrease the 
evaporation of dodecane. 
Cell density was monitored spectrophotometrically at 600 nm.  
4.5.4 Lycopene and amorpha-4,11-diene assay 
Intracellular lycopene content was extracted from 10- ȝ/ EDFWHULDO
culture (depending on the content of lycopene in the cells) in the stationary 
phase (24 h for LB, 2xYT and 2xPY, 48 h for 2xM9 and other defined 
media after induction). Cell pellets were washed with PBS, and lycopene 
was extracted by acetone. The lycopene content was quantified through 
absorbance at 472 nm using a 96-well microplate reader (Spectra Max 
190, Molecular Devices) and concentrations were calculated by 
interpreting the standard curve. Cell mass was calculated by correlating 
DCW with a reading of OD600 and used for calculating specific 
SURGXFWLYLW\ȝJO\FRSHQHJ'&:. 
The strains producing amopha-4,11-diene were cultured in defined media 
with the addition of another 25% (v/v) organic dodecane phase to extract 
amopha-4,11-diene [138]. Amopha-4,11-diene was extracted by diluting 5 
ȝ/GRGHFDQHSKDVHLQWRȝ/HWK\ODFHWDWHDQGDQDO\]HGRQDQ$JLOHQW
7980A gas chromatograph equipped with an Agilent 5975C mass 
spectrometer (GC/MS), by scanning at only 189 m/z ion (single-ion 
monitoring, SIM mode), using trans-caryophyllene as the internal standard. 
The temperature program for the GC/MS analysis was essentially as 
described [130]. 
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4.5.5 RNA purification and cDNA synthesis 
Total RNA from E. coli was prepared using TRIzol® reagent (Invitrogen) 
according to the manufacturer’s instructions. Total RNA was collected 
from samples in quadruplicate at each treatment time point. RNA 
concentration was quantified using a NanoDrop ND-1000 
spectrophotometer (Thermo Scientific). Eight hundred ng of total RNA 
ZHUH UHYHUVH WUDQVFULEHG LQD WRWDO YROXPH RIȝ/FRQWDLQLQJ ,PSURP,,
(Promega) for 60 min at 42°C according to the manufacturer’s instructions. 
The reaction was terminated by heating at 70°C for 10 min. 
4.5.6 Quantitative real-time PCR 
The cDNA levels were analyzed using a BioRad iCycler 4 Real-Time PCR 
Detection System (Bio-Rad) with SYBR Green I detection. Each sample 
was measured in duplicate in a 96-well plate (Bio-Rad) in a reaction 
mixture (25 µL final volume) containing 1x XtensaMix-SG (BioWORKS, 
Singapore), 200 nM primer mix, 2.5 mM MgCl2, 0.75 U of iTaq DNA 
polymerase (iDNA). Real time PCR was performed with an initial 
denaturation of 3 min at 95ºC, followed by 40 cycles of 20s at 95ºC, 20s at 
60ºC, and 20s at 72ºC. The primers used for real time PCR were given in 
supplementary data, and the reference gene used for normalization of real 
time PCR data was cysG [156]. 
The plasmid copy number was obtained by normalizing the copy number 
of plasmid resistant genes (ampicillin resistant gene for pBAD-SIDF and 
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chloramphenicol resistant gene for pAC-LYC) to the copy number of 
chromosomal gene ispE. Standard curves were constructed using 
linearized plasmids. 
4.5.7 Metabolites assay by LC-MS 
Metabolites were analyzed on the UPLC (Waters ACQUITY UPLC) – 
(TOF) MS (Bruker micrOTOF II) platform. Cell pellets were collected at a 
density of ~ 1 OD by centrifugation at 16,000 g for 1 min. The supernatant 
was then removed and the cell pellet was re-suspended in 30uL of double 
distilled water. 120 uL of 100% methanol was then added to the cell 
suspension and incubated at room temperature for 10 min. The solution 
was centrifuged at 16,000 g for 2 min, and 50 uL of the clear supernatant 
was collected for analysis. Five microliter of the clarified supernatant was 
injected into the reverse phase UPLC C18 column (Waters CSH C18 1.7 
ȝPPP [PP DQGVHSDUDWLRQZDVFDUULHG RXW DW D IORZ UDWH RI
0.15 mL/min with an aqueous mobile phase consisting of 15 mM acetic 
acid and 10mM tributylamine. Elution was carried out with methanol, in an 
increasing concentration gradient, as shown in Table 4-8. Electrospray 
ionization was used and (TOF) mass spectrometry setting was essentially 
as described [157]. 
Table 4-9. Mobile phase gradient used for the separation of DXP intermediates. 
Step Accumulative Time (mins) Aqueous solution* Methanol 
1 1.8 100% 0 
2 3.1 60% 40% 
4 4.9 60% 40% 
5 5.4 10% 90% 
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6 9.5 10% 90% 
7 10 100% 0 
*Aqueous solution: 15mM acetic acid and 10mM tributylamine 
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Chapter 5. TRANSPORTER ENGINEERING 
FOR THE PRODUCTION OF ISOPRENOIDS 
5.1 Introduction 
Microbial production is a sustainable approach to produce various 
chemicals and biofuels. Using tools developed in metabolic engineering, 
significant improvements have been achieved in titers and yields of these 
products. However, the high-titer production of the heterologous 
compounds often leads to inhibition of cell growth [35]. In addition, it was 
reported that for bio-based products, the cost of recovery and refinement 
is substantial. For example, in the manufacturing of carboxylic acid, 50% 
to 60% of production costs are attributed to recovery and refinement [158]. 
Bacteria have evolved the capability to secrete various compounds, native 
or heterologous, through the multidrug resistant (MDR) efflux pumps 
system [159]. There are five families of efflux pumps in E. coli that are 
associated with MDR. They are the ATP-binding cassette (ABC) 
superfamily, the major facilitator superfamily (MFS), the multidrug and 
toxic-compound extrusion (MATE) family, the small multidrug resistance 
(SMR) family and the resistance nodulation division (RND) family (Table 
5-1) [160]. The structures of efflux pumps can be made up of either a 
single component or multiple components. For example, the putative 
fosmidomycin efflux protein fsr has only a single component. Whereas 
acrAB-tolC complex, the most studied RND family pumps in E. coli, 
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consists of three components - the inner membrane protein acrB, the 
periplasmic adapter (or membrane fusion protein) acrA and outer 
membrane protein tolC (Figure 5-1). The substrates of the MDR efflux 
pumps are not restricted to antibiotics, but include many environmental 
and host-derived xeno-metabolites. Thus, these pumps have a general 
detoxification function in bacteria [161, 162] and have the potential to 
efflux various heterologous products.  
 
Table 5-1. Five categories of membrane transporters 
Acronym Full name 
MFS Major Facilitator Superfamily 
SMR Small Multidrug Resistance 
RND Resistance Nodulation Cell Division 
ABC ATP-Binding Cassette 
MATA Multidrug and Toxic Compound Extrusion 
 
 
Figure 5-1. Illustration of acrAB-tolC RND pump system. 
TolC (colourful), the outer membrane protein; acrA (yellow), the periplasmic adaptor (or 
membrane fusion protein); acrB (pink), the inner membrane protein. The acrAB-tolC 
pump system have various substrates (the asterisks with different colors). 
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Recently, there are increasing reports of the manipulations of different 
transporters to improve tolerance of the hosts to different adverse 
conditions and to increase yields of various products, summarized in  
Table 5-2. The use of transporters can also benefit the downstream 
recovery process by effluxing the products into the media that can then be 
in situ extracted using additional phase (for example, organic phase was 
used to extract AD [138]). In these studies, some studies are focused on 
the RND family transporters [35, 163] and some on the ABC family 
transporters [36], and as yet, there is no study that systematically explored 
different families in combinations. Although some heterologous efflux 
pumps were investigated in E. coli, the native transporters (acrAB-tolC 
[35], msbA [36]) were found to be most useful in E. coli. This could simply 
be due to the poor expression of functional heterologous pumps in 
different hosts. E. coli has many native MDR transporters which are 
known to handle highly diversified substrates and the potential use of 
these MDR transporters in efflux of AD has not been fully investigated. 
In this study, the effects of single deletion of genes of 21 selected MDR 
efflux pump on the AD production were investigated. It was found that the 
deletion of tolC significantly decreased the extracellular concentration of 
AD and concomitantly increased the intracellular concentration of AD. 
Furthermore, overexpression of tolC together with ABC family (msbA or 
macAB) or MFS family transporters (emrAB or emrKY) enhanced AD yield 
significantly. In addition, we also investigated the effects of single deletion 
TRANSPORTER ENGINEERING FOR THE PRODUCTION OF ISOPRENOIDS 
Page 97 | 196 
 
of these MDR genes on the efflux of phosphorylated compounds such as, 
1-deoxy-xylulose-5-phosphate (DXP) and 2-Methyl-D-erythritol-2,4-
cyclodiphosphat (MEC), two intermediates in the DXP pathway. 
 
Table 5-2. Recent publications using transporters to enhance the microbial productions 










The overexpression of variants of the native 
acrB enhanced growth rates of E. coli in the 








A ~4.4-fold, significant (P < 0.03) increase in 
secreted canthaxanthin was observed 
mediated by overexpressed EcoMsbA 
compared with the control following 96 h of 
aerobic incubation at 30 °C. 
A ~2.4- fold increase in secreted zeaxanthin 
mediated by StMsbA was achieved 





d pump from 
Alcanivorax 
borkumensis 
The strain that overexpressed the pump 
produced significantly more limonene than 






The strain overexpressing the efflux pumps 
showed substantially retarded cell growth 







The strain which overexpressed the rhtC 
gene obtained 50.2% higher production of L-
threonine than that obtained without rhtC 
amplification. 
And further amplification of the rhtA and rhtB 
genes resulted in a small increase in L-
threonin production. 
A 15.6% increase in 
L-threonine was 
observed with the 
deletion of tdcC 
which uptakes 
extracellular L-












Overexpression of heterologous MexB 
increased kaurene production by 70 %.  The 
combination of tolC and tolC and AcrB 
improved amorphadiene yield with 118 %, 
AcrA and tolC and AcrB improved kaurene 
yield with 104 %. 
/ [163] 
L-Valine YgaZH/valine exporter 
The overexpression of the ygaZH genes 
enhanced the production of L-valine.  And 
co-overexpression of the lrp and ygaZH 
genes was synergistic and led to a 2.13-fold 
increase in L-valine production. 
The level of L-valine 
production did not 
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Overexpression of potE gene in a low-copy 
plasmid led to retarded cell growth and 
lower putrescine production; While 
overexpression by replacement of native 
promoter of the speF-potE operon with a 





5.2.1 Identifying the pump candidates using single-gene 
knockout mutant 
The BW25113 strain and its 21 single gene knockout mutants were 
obtained from the Keio collection of gene knockout mutants [166]. These 
mutants were transformed with two plasmids, pBAD-dxs-idi-ispDF and 
pACM-ADS. The information about functions and categories of transporter 
genes was summarized in supplemental data (Table 5-6). The 21 pump 
encoding genes covered all the five families of efflux pumps, MFS family 
(bcr, cmr (or mdfA), emrD, emrK, fsr, mdtG, mdtH, mdtL, mdtM), RND 
family (mdtA (or yegM), cusC, acrD, mdtF, mdtE, acrA and acrB), SMR 
family (emrE and mdtJ), MATE (mdtK) and ABC family (macA), in 
addition, the outer membrane protein tolC was also included in the study. 
 
 
With single deletion of pump encoding genes, most of the extracellular AD 
titer was decreased significantly and this could be due to various reasons. 
As compared to the wild type, the final ODs of the strains with single 
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deletion of emrE, cmr, mdtM, mdtA, bcr, acrA, acrB and tolC were 
significantly reduced (P<0.005) (Figure 5-2A). As a result, the extracellular 
yield of AD similarly decreased accordingly (P<0.005) (Figure 5-2B). In 
contrast, cell density was not affected significantly with the single deletion 
of cusC, macA, mdtH, mdtK, acrD, mdtF or emrD. However, the 
extracellular production of AD of these mutants decreased significantly 
(P<0.005). Although the ODs of the strains with single deletion of mdtG 
and mdtJ were increased (P<0.005), the extracellular titer of AD 
decreased significantly (P<0.005). 
In addition, most of the gene deletions affected the AD productions both 
intra- and extra-cellularly. The single deletion of emrE, macA, mdtG, mdtH, 
mdtJ, mdtF, mdtA, bcr or acrA decreased both intracellular and 
extracellular concentration of AD significantly (P<0.005, Figure 5-3B&C). 
The knockout of tolC increased the intracellular AD production by 8.2 fold 
and concomitantly decreased extracellular AD production by about 90%. 
These data strongly supported the notion that tolC was involved in the 
secretion of AD. Interestingly, the copy number of pBAD-SIDF in the 
mutant strains (cusC, macA, mdtG, mdtH, mdtJ, acrD, mdtE, mdtL and 
mdtM) decreased significantly as compared to that in wild type strain 
(Figure 5-3A). However, the copy number of pACM-ADS remained 
unchanged to any significance in all the mutant strains (Figure 5-3B). 
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Figure 5-2. The effect of single-MDR-gene deletion on the cell density and the AD 
production.  
(A) OD at 48 h in single-MDR-gene knockout mutants. All the strains carried the two 
plasmids, pBAD-SIDF and pACM-ADS. (B) Extracellular AD production in single-MDR-
gene knockout mutants. (C) Intracellular extracellular AD production in single-MDR-gene 
knockout mutants. Stars indicated significance in two tailed Student's t-test, and all the t-
tests were calculated between knockout mutant and the wild type, **P<0.005 and 
***P<0.0005. 
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Figure 5-3. The effect of single-MDR-gene knockout on plasmid copy number. 
 (A) Fold change in the copy number of plasmid pBAD-SIDF. (B) Fold change in the copy 
number of plasmid pACM-ADS. The plasmid copy number were calculated as described 
in methods and materials. And they are presented as the fold change compared to that in 
the wild type strain. 
 
5.2.2 Reconstitution of tolC increased the efflux of AD in tolC 
mutant 
If tolC was involved with the efflux of AD, we speculated that reconstitution 
of tolC into the tolC mutant should increase the efflux in the mutant. The 













2.00 B. Fold change in the copy number of pACM-ADS 
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tolC gene was subcloned into RK2 vector and the plasmid was 
transformed into the tolC knockout mutant (tolC+ strain). In line with the 
hypothesis, the reconstitution of tolC in the mutant restored the level of 
effluxed AD from cells (Figure 5-4). Similarly, the knockout of tolC in 
BW25113 strain resulted in the extracellular AD concentration decreased 
from 2.31 g/L (wild type strain) to 0.65 g/L (tolC strain) and the intracellular 
AD concentration increased from 0.07 g/L (wild type strain) to 2.06 g/L 
(tolC strain). In the presence of RK2-tolC plasmid, the extracellular AD 
increased from 0.65 g/L (tolC strain) to 2.37 g/L (tolC+ strain), a level 
similar to that in the wild type strain. And the intracellular concentration of 
AD was decreased from 2.06 g/L (tolC+ strain) to 0.22 g/L when tolC was 
overexpressed. Interestingly, the reconstitution of tolC also restored cell 
growth as evident by the comparable cell density of the tolC mutant 
(TolC+) and the wild type. These results suggested that AD was not 









Wild type TolC TolC+
AD (mg
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Wild type TolC TolC+
OD 
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 “tolC” is the tolC knockout mutant, “tolC+” is the tolC mutant supplemented with tolC 
gene in the RK2 plasmid. All  the wild type, tolC and tolC+ strains carried plasmid pACM-
ADS, in addition, the tolC+ also carried plasmid RK2(amp)-T7-tolC. One fifth (v/v) 
dodecane was added into the media to capture the extracellular AD. 
 
5.2.3 Effects of reconstitution of efflux pumps in AD-producing 
strains   
As deletion of tolC resulted in decreased efflux of AD, it was worth 
investigating in greater detail of the effects of reconstitution of tolC on AD 
production. TolC is an outer membrane protein and can form complexes 
wtih three types of transport systems: ABC family (macAB), RND family 
(acrAB, acrEF, mdtABC, acrAD and mdtEF) and MFS family (emrAB, 
emrKY and entS) (Table 5-3) [167]. During the export of AD into the 
medium, AD has to traverse both inner membrane and outer membrane. 
Since the outer membrane channel tolC does not possess any substrate 
specificity, there may be some inner membrane proteins that regulate the 
export of AD across the inner membrane. Hence, it will be highly desirable 
to identify these inner membrane pumps involved in AD export. It is 
predicted then that the overexpression of these pumps together with tolC 
will likely to increase the yield or productivity of AD by driving the 
reversible reactions (dxr [168], ispG [169]  and ispH [170]) forward and 
reducing product inhibition [98] simply by shuttling AD out of cells. 
In addition to the tolC-related transporters, we also investigated a few 
MDR transporters (emrE, emrD, fsr, cmr, mdtM and mdtH) and the 
transporters in lipopolysaccharide (LPS) transport system (lptD, 
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lptCABFG, and msbA). LptD is an outer membrane protein that is required 
for LPS transport to the cell surface in E. coli. In addition, LptCBFG, an 
ABC transporter, is responsible for the release of LPS from the inner 
membrane [171]. LptA is a periplasmic protein which acts as a LPS 
chaperone or a bridge between the inner membrane and the outer 
membrane [172]. MsbA facilitates flipping of the lipid A-core structure 
across the inner membrane [173]. The reason we chose to examine LPS 
transporters was that ABC exporters are known to export extremely 
hydrophobic compounds, such as lipids, drugs and steroids, and AD was 
hydrophobic compound [174]. Furthermore, the overexpression of msbA 
has been reported to enhance the secretion of hydrophobic carotenoids 
[36]. 
 
Table 5-3. TolC-related transporter system 











Organic solvents , dyes and detergents as well 
as lipophilic antibiotics including novobiocin, 






Hydrophobic compounds such as carbonyl 
cyanide m-chlorophenylhydrazone, 






RND Highly homologous to the acrAB multidrug efflux system 













MFS Mitomycin C, enterobactin 
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Deoxycholate, SDS, novobiocin, kanamycin, 
tetracycline, nalidixic acid, norfloxacin, 








As shown in Figure 5-5, AD production in both early stage (8 h) and final 
stage (24 h) increased by more than 3 fold in the strains that 
overexpressed tolC-msbA, tolC-emrAB, tolC-emrKY or tolC-macAB. In 
addition, the overexpression of tolC, lptCABEF, tolC-mdtEF, tolC-acrEF or 
msbA increased AD yield by more than 2 fold. Noteworthy, the inner 
membrane LPS transport protein msbA has not been reported to interact 
with the outer membrane tolC, yet the co-overexpression of tolC and 
msbA have synergistic effect resulting in more AD produced than their 
single overexpression. AD production was also increased noticeably when 
lptD, tolC-acrD or tolC-acrAB was overexpressed. However, when emrE, 
emrD, fsr, cmr, mdtM or mdtH was overexpressed, the AD production was 
nearly abolished. The cell density of all the strains was similar, except that 
the OD of the strain with overexpression of mdtEF-tolC, acrEF-tolC and 
acrAB-tolC was lower. The results indicated that unexpectedly, many tolC-
related transporter system and LPS transporter msbA have positive 
effects on the AD production, especially ABC transporters (msbA and 
macAB) and MFS transporters (emrAB and emrKY) significantly increased 
the AD production.  
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Figure 5-5. AD production in strains with supplemental expression of efflux pumps. 
 (A) AD titers in different strains. (B) Cell density of different strains at 24 h. Stars 
indicated significance in two tailed Student's t-test, and all the t-tests were calculated 
between the strain with the overexpression of pump-coding gene and control strain, 
**P<0.005 and ***P<0.0005. 
 
5.2.4 Preliminary attempts to identify pump candidates for the 
efflux of DXP and MEC 
Recently, our group found that the intermediates DXP and MEC in the 
DXP pathway were exported and accumulated in the growth medium [129, 
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passively diffuse across cell membrane, it is likely that some efflux pump 
is responsible for the export out of cells. Identifying efflux pump of MEC is 
useful for both fundamental study of membrane transporters of E. coli and 
potential applications in metabolic engineering and synthetic biology. For 
instance, knockout of the pump would force these compounds to stay 
inside the cell, and thus the flux in the DXP pathway may be enhanced 
resulting in higher yields of final products. 
In order to systematically evaluate the potential roles of a variety of 
transporters in the efflux of DXP, gene knock-out strains of the same 
genetic background were obtained from the Keio collection of gene 
knockout mutants [166]. Preliminary analyses (Figure 5-6) demonstrated 
that the accumulation of extracellular DXP was less than the control strain 
in some of the knock-out mutants (e.g., fsr, emrE, cmr, etc). However, the 
corresponding intracellular DXP levels in the corresponding strains were 
either similar or even higher than the controls (eg. bcr, emrD, etc).  As this 
is a preliminary study, further work to evaluate if these particular strains 
that showed both an increase in efflux and the simultaneous accumulation 
of intracellular DXP (e.g., bcr, emrD) also show an increase in productivity 
of downstream isoprenoids.  
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Figure 5-6. Fold change of the concentration of DXP in the DXP pathway. 
(A) Extracellular DXP (nM/OD), (B) Intracellular DXP (nM/OD) (C) Extracellular MEC 
(nM/OD), (D) Intracellular MEC (nM/OD). Stars indicated significance in two tailed 
Student's t-test, and all the t-tests were calculated between knockout mutant and the wild 
type, *P<0.05 and **P<0.005. 
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5.3 Discussion 
Toxicity is a common and significant challenge with cell-based production 
[30, 35, 175]. As molecules have to traverse the inner and outer 
membranes of E. coli, the simple strategies of reducing the permeability of 
the outer membrane through decreasing porin expression or LPS 
modifications are not very useful in removing such toxic products in cells 
[175]. Microbial efflux pumps may serve as an alternative route to 
improving the export of native and heterologous compounds as they 
endow microbes with the ability to extrude a wide range of compounds 
such as antibiotics, solvents, cationic and lipophilic products [176-179]. 
With this, we hypothesized that E. coli has the capability to export AD or 
other similar heterologous hydrophobic compounds via native efflux 
pumps or other transport mechanisms. 
For a very long while, it was assumed that the volatile heterologous AD 
passively diffuses out of cells through cell membrane in E. coli. However, 
this is proven incorrect as we now show for the first time, that tolC is 
closely involved with AD efflux. Without tolC, even adding an organic layer 
into the cell culture to extract AD, the majority of AD (more than 80%) was 
found to be entrapped intracellularly. The outer membrane protein tolC is 
known to be involved in the extrusion of various harmful substances such 
as antibiotics [180], dyes [181], organic solvents [182] and detergents 
[183]. Furthermore, it was found that the export of some metabolites 
(porphyrin [182], cysteine [183], indole [183] and siderophores [184]) 
TRANSPORTER ENGINEERING FOR THE PRODUCTION OF ISOPRENOIDS 
Page 112 | 196 
 
involved tolC. TolC is also involved in the extrusion of intracellular 
metabolites such as signaling molecules such as cyclic AMP [185]. Thus, 
tolC mutant has pleiotropic effects, such as increasing susceptibility to 
antibiotics, cell division defects, changes in the expression of outer 
membrane porins, sensitivity to acid and decreased virulence [184].  
Consistent with the tolC deletion results, the overexpression of tolC 
transport complexes, tolC-emrAB, tolC-emrKY or tolC-macAB, significantly 
improved the AD production. AD production was also increased when 
single gene tolC, lptD or msbA was overexpressed. MsbA is an essential 
ABC transporter that exports charged lipid A across the inner membrane 
in E. coli [185]. It was reported that the overexpression of msbA was able 
to enhance the secretion of some carotenoids [36]. Interestingly, co-
overexpression of msbA and tolC has a synergetic effect on the AD 
production. These results indicated that multiple transporters are likely to 
be involved in the export of AD from cytoplasm. The intrinsic property of 
MDR transporters is that they are able to extrude various types of toxic 
heterologous compounds (e.g. antibiotics, biocides) [186]. Therefore, it is 
possible that more than one native transporter in E. coli is involved in the 
export of AD. Another interesting finding was that the overexpression of 
emrE, emrD, fsr, cmr, mdtM and mdtH nearly abolished the AD production 
due to unknown mechanisms, which could be due to their role in extruding 
the inducer IPTG. We have also overexpressed these transporters in 
lycopene-producing strains (Figure 5-5). However, none of these 
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transported was able to export this extremely hydrophobic compound, 
lycopene (data not shown). Similarly, the overexpression of another efflux 
pump, msbA, did not enhance the export of lycopene out of E. coli [36]. 
Interestingly, our previous study demonstrated the efflux of the metabolic 
intermediates in the DXP pathway, DXP and MEC [129, 157]. The efflux of 
these two intermediates reduces the carbon fluxes in the pathway and 
thus decreases the final yield and productivity of downstream products. 
Thus, the identification and subsequent knock out or knock down of 
responsible efflux pumps should extend previous observations.  
Preliminary studies showed that the absence of some pumps may affect 
the levels of extracellular and intracellular levels of DXP. These 
observations must be further confirmed and extended before any 
conclusions can be confidently deduced. Furthermore, in the next chapter, 
we attempted to use mathematical simulation of the DXP pathway to study 
the efflux and the kinetic behavior of the intracellular pathway. 
5.4 Conclusion 
Through single gene deletion, we found that outer membrane protein tolC 
was closely involved in the efflux of AD in E. coli. And the overexpression 
of tolC-emrAB, tolC-emrKY or tolC-macAB significantly improved the AD 
production. This study indicated that pump engineering is an effective 
approach in metabolic engineering to construct high-yield AD producers. 
Beyond this, the strategy herein may be used to enhance the production 
of other kinds of heterologous compounds. 
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5.5 Methods and materials 
5.5.1 Strains, plasmids and transporter genes 
BW25113 (ǻDUD'-DUD% ǻODF=UUQ%- Ȝ- rph- ǻUKD'-
rhaB)568 hsdR514) and its single gene knockout mutant were used in the 
screening experiments. All of them were from the Keio collection of gene 
knockout mutants [187]. .0*ǻUHF$ǻHQG$'( strain [13] was 
used for AD production with overexpression of transporters. 
Selected genes and operons were amplified by PCR from MG1655 
ǻUHF$ǻHQG$ DE3 genomic DNA with their putative upstream ribosome 
binding sites. All the genes and operons were inserted into modified RK2 
(amp) plasmid [188] with the Pm promoter replaced with TM1 (T7 variant) 
promoter. TolC was inserted into RK2 first to generate RK2-tolC. Selected 
operons (macAB, acrAB, emrAB, arcEF, emrKY, entS, acrD, mdtEF and 
msbA) were also inserted into RK2-tolC to generate artificial operons with 
tolC. The genes (MdtM, mdtH, fsr, cmr, emrD, emrE, msbA and lptD) were 
inserted directly into RK2 plasmid. The operons lptCAB and lptFG were 
co-inserted into RK2 plasmid. The gene ADS was inserted into modified 
pAC plasmid with the araBAD promoter to obtain pACM-ADS. All the 
constructions used CLIVA methods [129] and the phosphorothioated 
primers used were shown in Table 5-5. The transporter genes studied in 
this chapter and their main functions are listed in Table 5-6. 
 
Table 5-4. Bacterial strains, plasmids and primers used in this study 
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Strains, plasmids 




Strains   
BW25113 ǻDUD'-DUD%ǻODF=UUQ%-Ȝ- rph-ǻUKD'-rhaB)568 hsdR514 [166] 
fsr %:ǻIVUNDQ [166] 
emrE %:ǻHPU(NDQ [166] 
cusC %:ǻFXV&NDQ [166] 
cmr %:ǻFPUNDQ [166] 
macA %:ǻPDF$NDQ [166] 
mdtG %:ǻPGW*NDQ [166] 
mdtH %:ǻPGW+NDQ [166] 
mdtJ %:ǻPGW-NDQ [166] 
mdtK %:ǻPGW.NDQ [166] 
emrK %:ǻHPU.NDQ [166] 
acrD %:ǻDFU'NDQ [166] 
mdtF %:ǻPGW)NDQ [166] 
mdtE %:ǻPGW(NDQ [166] 
mdtL %:ǻPGW/NDQ [166] 
mdtM %:ǻPGW0NDQ [166] 
mdtA %:ǻPGW$NDQ [166] 
bcr %:ǻEFUNDQ [166] 
emrD %:ǻHPU'NDQ [166] 
acrA %:ǻDFU$NDQ [166] 
acrB %:ǻDFU%NDQ [166] 
tolC %:ǻWRO&NDQ [166] 
MG1655 .0*ǻUHF$ǻHQG$'( [13] 
Plasmids   
RK2-emrE RK2 carrying emrE under TM1 promoter control This study 
RK2-emrD RK2 carrying emrD under TM1 promoter control This study 
RK2-fsr RK2 carrying fsr under TM1 promoter control This study 
RK2-cmr RK2 carrying cmr under TM1 promoter control This study 
RK2-mdtM RK2 carrying mdtM under TM1 promoter control This study 
RK2-mdtH RK2 carrying mdtH under TM1 promoter control This study 
RK2-tolC RK2 carrying tolC under TM1 promoter control This study 
RK2-lptCABFG RK2 carrying lptCABFG artificial operon under TM1 promoter control 
This study 
RK2-lptD RK2 carrying lptD under TM1 promoter control This study 
RK2-msbA RK2 carrying msbA under TM1 promoter control This study 
RK2-tolC-entS RK2 carrying tolC-entS artificial operon under TM1 promoter control 
This study 
RK2-tolC-msbA RK2 carrying tolC-msbA artificial operon under TM1 promoter control 
This study 
RK2-tolC-emrKY RK2 carrying tolC-emrKy artificial operon under TM1 promoter control 
This study 
RK2-tolC-acrD RK2 carrying tolC-acrD artificial operon under TM1 promoter control 
This study 
RK2-tolC-acrAB RK2 carrying tolC-acrAB artificial operon under TM1 promoter This study 
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control 
RK2-tolC-emrAB RK2 carrying tolC-emrAB artificial operon under TM1 promoter control 
This study 
RK2-tolC-macAB RK2 carrying tolC-macAB artificial operon under TM1 promoter control 
This study 
RK2-tolC-mdtEF RK2 carrying tolC-mdtEF artificial operon under TM1 promoter control 
This study 
RK2-tolC-acrEF RK2 carrying tolC-acrEF artificial operon under TM1 promoter control 
This study 
pBAD-dxs-idi-ispDF pBAD carrying dxs-idi-ispDF artificial operon under araBAD promoter control [24] 
pACM-ADS pAC carrying ADS under araBAD promoter control This study 
pACM-SAAI pAC carrying dxs-idi-ispA-ADS under T7 promoter control [129] 
pET-lacI pET plasmid carrying lacI [129] 
 































TRANSPORTER ENGINEERING FOR THE PRODUCTION OF ISOPRENOIDS 



























Full name Function 




Expression of fsr has been shown to confer resistance to 
the isoprenoid fosmidomycin 




Overexpression of mdfA has demonstrated that it confers 
resistance to tetracycline, chloramphenicol, erythromycin, 
some aminoglycosides and fluoroquinolones, and organic 
cations such as ethidium bromide. Deletion of mdfA 
resulted in increased susceptibility to ethidium bromide 
and benzalkonium chloride. Overexpression of mdfA also 
results in spectinomycin sensitivity and isopropyl-Ǻ-D-
thiogalactopyranoside (IPTG) exclusion due to unknown 
mechanisms. 




EmrD is a multidrug efflux protein involved in adaptation to 
low energy shock (exposure to uncouplers of oxidative 
phosphorylation) in E. coli 






Overexpression of the gene in E. coli has shown that it 
confers resistance to a range of toxic compounds 
including ethidium, methyl viologen, tetracycline, 
tetraphenylphosphonium (TPP+), erythromycin, 
sulfadiazine, acriflavin, crystal violet, and benzalkonium. 
EmrE also transports the osmoprotectants betaine and 
choline and plays a role in osmotic regulation of E. coli K-
12. 




Overexpression of the cloned yceL gene in a drug-
sensitive background strain resulted in a two-fold increase 
in resistance to norfloxacin and enoxacin 





Overexpression of the cloned mdtM gene in a drug-
sensitive background strain results in a four-fold increase 
in resistance to acriflavine and a two-fold increase in 
resistance to chloramphenicol, ethidium bromide and 
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tetraphenylphosphonium bromide (TPP). Strains 
lacking mdtM show impaired growth in the presence of 
ethidium bromide and chloramphenicol compared to wild 
type. Overexpression of cloned mdtM in both a wild type 
background and in an mdtM null background results in 
increased resistance to ethidium bromide and 
chloramphenicol. MdtM is functional in whole cell ethidium 
bromide transport assays and efflux is disrupted by the 
addition of the ionophore, carbonyl cyanide 3-
chlorophenylhydrazone (CCCP) 




A member of the ATP Binding Cassette (ABC) 
Superfamily of transporters, is essential for the 
translocation of the lipid A-core from the inner leaflet to the 
outer leaflet of the inner membrane 






complex - LptD 
subunit 
The LptD (lipopolysaccharide transport) protein is an 
essential outer membrane (OM) protein which, in complex 
with LptE, functions to assemble lipopolysaccharides at 
the surface of the OM. LptD is involved in determining the 
level of organic solvent tolerance in E. coli 
lptE Lipoproteins 







complex - LptE 
subunit 
LptE (formerly RlpB) is involved with lipopolysaccharide 
assembly in the outer membrane as part of the outer 
membrane LPS assembly complex with LptD. LptE is one 
of two (along with LptD) so-called rare lipoproteins in E. 









LptCBFG is an ATP Binding Cassette (ABC) transporter 
which facilitates the release of LPS from the inner 
membrane. LptA is a periplasmic protein initially thought to 
be an LPS chaperone but now believed to act as a bridge 
between the inner membrane and the outer membrane.  









MacAB, also known as YbjYZ, probably forms a complex 
with outer membrane protein tolC to confer macrolide 










AcrAB and tolC make up a three-component proton 
motive force-dependent multidrug efflux system which 
confers resistance to multiple antimicrobial agEntS. The 
complex is the major contributor to the intrinsic resistance 
of E. coli to organic solvEntS, dyes and detergEntS as 
well as lipophilic antibiotics including novobiocin, 










Expression of emrB has been shown to confer resistance 
to hydrophobic compounds such as carbonyl cyanide m-
chlorophenylhydrazone, tetrachlorosalicylanilide, 










AcrEF is a multidrug efflux system in E. coli that is highly 
homologous to the AcrAB multidrug efflux system. 
Plasmid overexpression of AcrEF suppresses the hyper-
drug sensitivity of AcrAB deletion mutants  however the 
AcrEF system is not thought to play a large role in drug 
resistance as AcrEF deletion mutants do not display a 
drug sensitive phenotype. The level of expression of 
AcrEF is thought to be low under laboratory conditions. 
Plasmid overexpression of AcrF is able to complement an 










EmrK and EmrY show sequence similarity to EmrA and 
EmrB respectively. Cloning of the promoter along with the 
creation of an EmrK-lacZ fusion revealed that expression 
was increased in the prescence of a sub inhibitory 
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concentration of tetracyclin, chloramphenicol, or salicylate 
but not by carbonylcyanide m-chlorophenylhydrazone, 













MdtA is a membrane fusion protein functioning as a 
component of the MdtABC RND-type drug exporter. 
Membrane fusion proteins serve as 'adaptor' proteins that 
connect an inner membrane transporter to an outer 
membrane channel such as tolC - they are believed to be 
largely periplasmic. These genes code for an RND-type 
drug export distribution (RND) complex, MdtABC, which 
confers resistance against bile salt derivatives, sodium 










EntS was identified in a screen for genes that reduce the 
lethal effects of stress. An EntS insertion mutant is more 
sensitive than wild type to mitomycin C and other 
stresses. EntS has been implicated in arabinose efflux. 
The EntS protein is a member of the major facilitator 
superfamily (MFS) of transporters. Based on sequence 
similarity, it functions as a proton-driven efflux system. 
Siderophore nutrition assays have shown that an EntS 
mutant is unable to export enterobactin efficiently to 
alleviate iron deprivation, though some export does still 
occur through another mechanism. Deletion of tolC 
abolishes enterobactin export completely. Enterobactin 
appears to have more than one mechanism for export to 
the periplasm, one involving EntS, but tolC is the only 
outer membrane channel that can export enterobactin 










Studies performed using overexpression of the response 
regulator EvgA conferred multiple drug resistance (MDR) 
to E. coli cells lacking the AcrAB MDR transporter. The 
plasmid-containing cells showed drug resistance against 
deoxycholate (>32-fold compared with control level), 
doxorubicin (64-fold), rhodamine 6G (16-fold), 
erythromycin (8-fold), crystal violet (8-fold), benzalkonium 
(8-fold), and sodium dodecyl sulfate (SDS) (4-fold). EvgA 
is known to positively regulate the gene expression of the 
drug resistance system EmrKY, but cells in which only 
EmrKY is overproduced acquire resistance only to 
deoxycholate (8-fold). Deletion mutation studies were 
conducted in which MdtEF was removed by chromosomal 
in-frame mutation. The MdtEF deletion strain showed no 
increased drug resistance (except for deoxycholate) when 
evgA was overexpressed. Since overexpression of EvgA 
normally confers an MDR phenotype, these results 
strongly suggest that the EvgA-induced MDR is due to 
stimulation of MdtEF gene expression. 
cusC RND 









The copper/silver transporting efflux system, CusCFBA, is 
one of at least three systems involved in copper 
resistance. CusB is a member of the membrane fusion 
protein (MFP) family. CusC is the outer membrane factor 
which forms a channel in the outer membrane. CusA is 
the resistance-nodulation-division (RND) permease. CusF 
is the periplasmic copper binding protein. CusCBA is a 
tripartite complex that spans both the inner and outer 
membrane and, along with the periplasmic chaperone 
CusF, functions to export copper and silver ions from both 









Overexpression of the cloned mdtG gene in a drug-
sensitive background strain resulted in a two-fold increase 
in resistance to deoxycholate and a four-fold increase in 
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resistance to fosfomycin. 
mdtJ 
(ygF) SMR 






Episomal expression of mdtJI resulted in excretion of 
spermidine in transport assays and allowed recovery of 
cells from spermidine toxicity due to over-accumulation. 
Drug-resistance studies indicate that overexpression 
of mdtJI in an expression vector conferred increased 
resistance to deoxycholate (4-fold), nalidixic acid (2-fold), 
fosfomycin (2-fold), and SDS ( 2-fold). Episomal 
expression of mdtJ causes inhibition of cell growth, 
compared to wild type 
mdtL 
(yidY) MFS 
1176 bp / 
391 aa 




Overexpression of the cloned yidY gene in a drug 
sensitive background strain resulted in a four-fold increase 
in resistance to chloramphenicol, ethidium bromide and 
TPP. 




Expression of the cloned mdtK gene conferred increased 
resistance to norfloxacin, ciprofloxacin, acriflavine, and 
tetraphenylphosphonium. E. coli strains 
expressingnorM or mdtK showed elevated resistance to 
several antimicrobial agents, including fluoroquinolones, 
ethidium bromide, rhodamine 6G, acriflavine, crystal 
violet, berberine, doxorubicin, novobiocin, enoxacin, and 
tetraphenylphosphonium chloride. 





AcrD is believed to form a tripartite complex with AcrA (an 
MFP) and tolC for multidrug transport. AcrD shows amino 
acid sequence similarity with the E. coli RND multidrug 
efflux proteins AcrB and AcrF. Experiments using 
proteoliposomes show the AcrAD-tolC complex is able to 
transport drugs from both the cytoplasm and the periplasm 
to the extracellular space. Disruption of the acrD gene did 
not result in hypersusceptibility to lipophilic and 
amphiphilic drugs, but did result in hypersusceptibility to a 
variety of aminoglycosides including amikacin, gentamicin, 
tobramycin, kanamycin, neomycin, erythromycin, and 
polymyxin B. Expression of acrD on a multicopy plasmid 
from native or IPTG inducible promoters in 
an acrAB mutant resulted in increased resistance to 
deoxycholate, SDS, novobiocin, kanamycin, tetracycline, 
nalidixic acid, norfloxacin, fosfomycin, bile acids, fusidic 
acid, and progesterone. 
bcr MFS 1191 bp / 396 aa 
Multidrug efflux 
transporter Bcr 
Bcr is a probable multidrug efflux protein, expression of 
which has been shown to confer resistance to 
bicyclomycin and sulfathiazole. 
 
5.5.2 Quantification of intracellular and extracellular AD and 
MEC  
The quantification of intracellular and extracellular AD and MEC was 
illustrated in Figure 5-7. One milliliter fresh medium in 14mL BD Falcon™ 
tube was inoculated with 1% overnight grown cell culture. And the medium 
was covered by 200 µL dodecane (with 100 mg/L ȕ-caryophyllene). When 
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the OD reaches about 5, five microliter dodecane was transferred into 495 
µL ethyl acetate (Extracellular AD). And 400 µL cell culture was 
transferred into 1.5 mL tube and centrifuged to separate the cell pellets 
from the media. The obtained supernatant was diluted 20X by 100% 
methanol and centrifuged to remove the salts (Extracellular MEC). The 
cell pellets were re-suspended into 100 µL double distilled water. Sixty 
microliter ethyl acetate and 10 mg 0.1 mm BioSpec glass beads were 
added into the cell suspension and was shaken for 10 min at 4 °C to lyse 
the cells and extract the intracellular AD (ethyl acetate phase) and MEC 
(water phase). MEC was quantified on the UPLC (Waters ACQUITY 
UPLC) – (TOF) MS (Bruker micrOTOF II) platform [24]. AD was measured 
using Agilent 7980A gas chromatograph equipped with an Agilent 5975C 
mass spectrometer (GC/MS) as previously reported [130].   
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Figure 5-7. Protocol for the quantification of intracellular and extracellular AD and MEC. 
 
5.5.3 Quantification of plasmid copy number  
The plasmid copy number was obtained based on real-time quantitative 
PCR data. It was calculated by normalizing the copy number of plasmid 
resistant genes (ampicillin resistant gene for pBAD-SIDF and 
chloramphenicol resistant gene for pACM-ADS) to the copy number of 
chromosomal gene cysG. 
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Chapter 6. KINETIC STUDY OF THE DXP 
PATHWAY 
6.1 Introduction 
To identify the rate-limiting steps in the DXP pathway in vivo, a sequential 
method was previously used where single gene in the pathway was 
individually overexpressed to identify gene targets, followed by screening 
of two-gene combinations using the identified genes, and then three-gene 
combinations, until all the combinations of identified targets were tested 
[19]. Obviously, this method was very tedious and time-consuming. In 
silico modeling offers a rapid and predictive way to optimize a pathway or 
a network. To obtain such a computational model, a robust and 
controllable system is required for the generation of reliable experimental 
data. The DXP pathway is a linear pathway and starts from the conversion 
of pyruvate (PYR) and glyceraldehyde-3-phosphate (GAP) to DXP 
catalyzed by DXP synthase (encoded by gene dxs). Glucose is used to 
provide energy and to produce biomass and metabolites. As the glycolytic 
network is complex, it is very difficult to calculate or measure the ratio of 
carbon that enters into the DXP pathway from glucose. On the other hand, 
it was reported that D-xylulokinase (encoded by gene xylB) was able to 
phosphorylate 1-deoxy-D-xylulose (DX) to DXP [187]. With the 
overexpression of xylB, it is possible to construct an artificial semi-closed 
system in which DX is exclusively used to produce carbon fluxes in the 
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DXP pathway. And using 13C labeled glucose and 12C DX, it is possible to 
differentiate the carbon flux from either the central pathway or from DX. 
In addition to the dynamics of the intracellular metabolites, we were also 
interested in studying the kinetics of extracellular metabolites and their 
relationship with the dynamics of the intracellular metabolites. DXP and 
MEC were found to be effluxed into the media when they were over 
produced [129]. The efflux of DXP and MEP not only affect the kinetics of 
the pathway and they may play a regulatory role as a signaling molecule. 
For example, it was also hypothesized that the carbon flux in the DXP 
pathway mainly accumulated as MEC, due simply to the inefficient activity 
of HMBPP synthase or limited availability of cofactors for the enzyme 
[157]. An established kinetic model of both intracellular and extracellular 
metabolites can facilitate validation of such hypothesis. 
In this study, we first constructed and tested the semi-closed dual-flux 
platform using 13C glucose and 12C DX. We then applied this platform to 
study the kinetics of the intracellular and extracellular metabolites for two 
genotypes. Finally, the S-system model was attempted to simulate the 
kinetic data. 
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6.2 Results 
6.2.1 Experimental design 
6.2.1.1 Construction of the dual flux system 
As shown in Figure 6-1, there are two routes of carbon to flux into the DXP 
pathway: to be converted from PYR and GAP (central pathway) by D-
deoxyxylulose-5-phosphate synthase (dxs) or from DX (synthetic pathway) 
which is catalyzed by D-xylulokinase (xylB). To study the kinetics of the 
DXP pathway, the expressions of dxs and xylB were controlled 
independently. The cells were grown in the defined media with D-glucose-
13C6 (13C Glu) as the only carbon source, thus all the DXP intermediates 
from central pathway were 13C labeled. Whereas all the carbon fluxes from 




Figure 6-1. The semi-closed dual-carbon-flux system of the DXP pathway.  
DX, 1-deoxy-D-xylulose; PYR, pyruvate; GAP, glyceraldehyde-3-phosphate; DXP, 1-
deoxy-D-xylulose-5-phosphatec; MEP, methylerythritol phosphate; CDPME, 4-
57
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diphosphocytidyl-2-C-methyl-D-erythritol; CDPMEP, 4-diphosphocytidyl-2-C-methyl-D-
erythritol-2-phosphate; MEC, 2-C-methyl-D-erythritol-2,4-diphosphate; HMBPP, 1-
hydroxy-2-methyl-2-(E)-butenyl-4-diphosphate; IPP, isopentenyl diphosphate; DMAPP, 
dimethylallyl diphosphate; GPP,  geranyl pyrophosphate; FPP, farnesyl pyrophosphate; 
AD, amorpha-4,11-diene. RK2A uses the P1 promoter induced by m-toluic acid, and 
pACM uses the T7 promoter induced by IPTG. IAA refers to the operon idi-ispA-ADS. 
 
Our initial intention was to maintain the original system as much as 
possible; therefore, the 12C carbon flux from DX was minimized. It was 
assumed that the 12C flux acted as a tracer for the kinetic behavior of the 
system and did not perturb the endogenous system significantly. To 
minimize the 12C carbon flux from DX, a low-copy plasmid RK2A with the 
weaker P1 promoter was used to carry the gene xylB (plasmid RK2-xylB). 
While the dxs was overexpressed in the higher copy vector pET, 
controlled by the stronger T7 promoter. To facilitate studies on the effect 
of the kinetics of the pathway on the production of AD, idi-ispA-ADS was 
co-overexpressed with dxs in the pET vector (plasmid pACM-SIAA).  
Using this system, a preliminary study was first carried out. As shown in 
Figure 6-2, both the amounts of 13C and 12C DXP and MEC in the DXP 
pathway were successfully detected. However, MEP in the DXP pathway 
was not detected. The MS peak of 13C MEP coincided with a background 
MS peak, therefore, it was not accurately quantified. Failure to detect 12C 
MEP was likely to be due to the concentration of MEP being too low to be 
detected in this condition. To tackle this issue, the RK2A vector was 
replaced with higher copy-number pBAD vector with araBAD promoter 
(plasmid pBAD-xylB). As a result, the 12C MEP was then detected despite 
its concentration (0.3 nmol/g DCW) was one order of magnitude lower 
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than DXP (5 nmol/ g DCW) and MEC (2 nmol/ g DCW) (Figure 6-3). The 
concentration of 12C DXP, MEP and MEC were increased but not of 13C 
labeled metabolites, indicative that the expression of xylB was 




Figure 6-2. The kinetic data of the dual-flux system. 
Samples were collected at 30 min, 60 min, 120 min and 180 mins after feeding of DX. 
The medium used in this study was MC defined media, and the cells were incubated at 


































































KINETIC STUDY OF THE DXP PATHWAY 




Figure 6-3. The DXP intermediates in the dual-flux system with the plasmid pBAD-xylB. 
 
6.2.1.2 Quantification of DX 
13C glucose and DX were quantified using GCMS. In order to make 
glucose and DX volatile for quantification by GCMS, these compounds 
were derivatized using methoxime-trimethylsilylation. As shown in Figure 
6-4, the ions m/z 323 and ions m/z 205 have large mass numbers and 
relatively high intensities, thus they were chosen as monitor ions for 13C 
glucose and DX. Using these ions intensity and the concentration of 
glucose and DX, we established the standard curves for 13C glucose and 
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Figure 6-4. The mass spectra of methoxime trimethylsilylated 13C glucose (A) and DX (B) 
 
  
Figure 6-5. The standard curve for 13C glucose and DX 
 
6.2.2 Data collection by LCMS and GCMS 
Two experimental conditions were chosen to study the kinetics of the DXP 
pathway. One was the overexpression of dxs with idi-ispA-ADS (strain 
MG001), and the other one was the overexpression of dxs-dxr with idi-
ispA-ADS (strain MG002). As shown in Figure 6-1, dxs is the first enzyme 
and dxr is the second enzyme in the DXP pathway. Therefore, perturbing 
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MS Peak area 
DX standard curve 
y = 1E-07x - 0.1544 
















MS peak area 
13C glucose standard curve 
KINETIC STUDY OF THE DXP PATHWAY 
Page 130 | 196 
 
the system by dxs or dxs and dxr can be a good starting point to 
understand how the overexpression of dxs and dxr affect the kinetics of 
the pathway. 
The kinetic data for studies using MG001 and MG002 were shown in 
Figure 6-6. DXP, MEP and MEC in the DXP pathway were detected, but 
CDPME and CDPMEP were not detected. This was likely due to the 
efficient conversion of CDPME and CDPMEP to MEC [189]. Because the 
cells were dividing during the sampling period, all the concentrations of 
intracellular and extracellular metabolites were normalized to the cell 
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Figure 6-6. The kinetic data of the intermediates in the DXP pathway. 
A, C, E and G are the kinetic data of intracellular metabolite, extracellular metabolites, 
extracellular DX and cell density for strain MG001, respectively; and B, D, F and H are 
the kinetics data of intracellular metabolite, extracellular metabolites, extracellular DX and 
cell density for strain MG002, respectively. The time of feeding DX was set as the starting 
point (0 min). 
 
In MG001, the overexpression of dxs resulted in the gradual accumulation 
of intracellular DXP and peaked at around 40 min and then started to 
decrease. Intracellular MEP and MEC increased at the first 40 min and 
maintained over the period of the study. As expected, the extracellular 
DXP and MEC accumulated over the time, whereas the extracellular MEP 
increased at the first 30 min and plateaued. In MG001, the intracellular 
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This is reasonable as only dxs in the pathway was overexpressed so that 
more DXP was produced than consumed. 
When dxs and dxr were co-overexpressed (MG002), the intracellular 
concentration of DXP was almost undetectable over the period of the 
study. As a result, extracellular DXP did not accumulate. The intracellular 
concentration of MEP was increased initially and started to decrease after 
about 40 min. Similar to MEP, intracellular MEC increased initially and 
peaked at 90 min (later than MEP) and then started to drop. The 
extracellular MEP and MEC were found to increase gradually but their 
rates of increase were decreased at later stage.  
As compared to MG001, the intracellular concentration of DXP was much 
lower while the concentrations of MEP and MEC were higher in MG002. 
This was likely to be due to the overexpression of dxr along with dxs in 
MG002 and thus DXP was efficiently converted into MEP. And the ispDEF 
complex [189] efficiently converted MEP to MEC without accumulating 
high concentrations of CDPME and CDPMEP. 
6.2.3 Kinetic Modeling of the DXP pathway 
6.2.3.1 S-system model of the DXP pathway 
The S-system structure, a form within Biochemical Systems Theory (BST), 
is one of the most promising canonical nonlinear models in metabolic 
modeling [188].  We attempted to use the S-system model to simulate the 
kinetic data in Figure 6-6. The model is constructed by approximating flux 
with products of power-law functions. In this model, two assumptions were 
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made. First, we assumed all the 12C carbon from DX was efficiently 
converted into DXP intracellularly, thus the reaction rate of DXP could be 
calculated from the levels of DX in the media. Second, we assumed that 
the efflux rate was the function of intracellular metabolites, and to be 
specific, they also followed the power-law structure of chemical reaction. 
From these two assumptions, the S-system equations for the DXP 
pathway were as follows: 
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         Equation 6-1, 
where X1 represented the DX concentration in the media, and it was 
determined by the conversion rate of DX into DXP. X2 represented the 
intracellular concentration of DXP which was determined by the 
conversion of DX into DXP, the efflux of DXP and consumption of DXP by 
dxs. X3 and X4 represented the intracellular concentrations of MEP and 
MEC, respectively, and they were calculated similarly to that of 
intracellular DXP. X5, X6 and X7 represent the extracellular 
concentrations of DXP, MEP and MEC, respectively, and they were 
determined based on their own efflux rate. 
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6.2.3.2 Data regression 
Although two parameter-estimating approaches [111, 117] were used 
initially, the experimental data (MG001 in Figure 6-6) could not be 
successfully fitted using the S-system model (Equation 1-1), especially the 
intracellular MEP (red line in Figure 6-7). This could be due to ill condition 
of the non-linear dynamic system caused by the data structure or the 
parameter estimation approaches employed. In addition, the total 
experimental data points were relatively few (only 7 points) where a single 
or two inaccurate data points would have produced unacceptably large 
deviations thus, limiting the modeling.  
A B 
  
Figure 6-7. Parameter estimation for the kinetic data of MG001. 




Various valuable products can be produced through the DXP pathway [2], 
however, the capability of the pathway was limited by our poor 
understanding of the kinetic behavior of the DXP pathway. Therefore, in 
this chapter, a MS-based offline quantitative approach was developed. 
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Using D-xylulokinase, we created a controllable artificial branch entry into 
the DXP pathway. Using unlabeled and labeled carbons to differentiate 
the carbon flux from central pathway or from artificial branch, the relatively 
good time-course data for the DXP pathway were obtained in Figure 6-6. 
As the successful parameter estimation is dependent on the availability of 
good quality experimental data sets, the experimental data obtained in this 
study may be used to develop a model to describe the pathway kinetics.  
Based on the kinetic data obtained in Figure 6-6, the efflux of extracellular 
metabolites was likely to be dependent on the concentration of the 
intracellular metabolites. In our model, we hypothesized that the efflux rate 
was the power law function of the intracellular concentration. This 
hypothesis may be incorrect. As the data shown in Figure 6-8, the initial 
efflux rate of DXP and MEC was zero when the intracellular concentration 
was low. Furthermore, the efflux rate of MEC gradually increased with 
increasing intracellular MEC concentrations and they were highly 
correlated (R2 of DXP = 0.877, R2 of MEC = 0.923). Eventually, the efflux 
rate reached the maximal when the intracellular concentration was above 
certain level, where for MEC, when the intracellular MEC was above 0.8 
µM, the efflux rate did not increase but decreased a bit further as the 
intracellular MEC increased. This observation was unexpected and more 
evidence is required to support and validate the hypothesis. And because 
of the significant effect of the efflux on the intracellular carbon flux and 
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pathway kinetics, once the relationship is confirmed, it should be 








Figure 6-8. Efflux study of DXP and MEC. 
(A) The time course of intracellular and extracellular DXP; (B) The time course of 
intracellular and extracellular MEC; (C) The efflux rate of DXP versus its intracellular 
concentration; (D) The efflux rate of MEC versus its intracellular concentration. The strain 
used in the experiment was MG1655 DE3 with the operon dxs-idi-ispDF knocked into its 
genomic DNA. And pBAD-xylB was transformed into the strain. 
 
Metabolic steady state is the prerequisite for kinetics study, which means 
that all intermediate concentrations are constant and all the fluxes are in 
balance throughout the experiment. In chemostat with continuous 










































Intracellular MEC Extracellular MEC









Intracellular concentration of DXP (µM) 










Intracellular concentration of MEC (µM) 
Efflux rate of MEC versus the intracellular MEC 
KINETIC STUDY OF THE DXP PATHWAY 
Page 137 | 196 
 
process, a metabolic steady state only exist during the exponential growth 
phase, when the growth rate is constant [190]. Therefore, the DX feeding 
and sampling were conducted at exponential phase. 
The interval between two time points was 30 min, which was not ideal for 
kinetics study. This time intervals were simply due to technical limitations 
where it took about 15 min to process the samples (OD measuring, 
collection of cells, centrifugation and separation). To enhance the 
precision of data obtained at these time points, it may be better to develop 
an online monitoring system. For example, Matthias et al [191] designed 
an MS-base quantitative real-time analysis system and successfully 
studied in vitro network using a cell free system. The advantage of the 
system is that it can pinpoint changes in metabolite concentration after 
perturbation to a certain enzyme in the context of the system. Another 
approach to design online monitoring system is to use metabolite 
biosensor. The in vivo 13C nuclear magnetic resonance (NMR) is another 
promising method to investigate the in vivo flux distribution through the 
catabolic pathways [192] . Recently, novel biosensors based on flavonoid-
responsive transcriptional regulators were developed [193], and there was 
a linear correlation between the fluorescence intensity and metabolite 
concentration using the biosensors. Hence, the use of an online 
monitoring system using the metabolite biosensor may circumvent the 
technical issues faced in this preliminary study in the future. 
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6.4 Conclusion 
In an attempt to gain an understanding of the kinetics of the DXP pathway, 
an alternative supply of the first precursor (DXP) in the pathway was 
explored by the addition of DX. The carbon fluxes in the pathway were 
quantified by MS based methods. Using this system, we managed to 
capture some kinetic data of the DXP pathway when dxs alone or dxs and 
dxr were overexpressed. It was found that the efflux rates of DXP and 
MEC were dependent on their intracellular concentrations. 
6.5 Methods and materials 
6.5.1 Media and strains 
The MC media used in the modeling work was defined media revised from 
Rersenberg media [142], in which citric acid and thiamine were removed 
from the media so that the only carbon source was glucose. The media 
contained 5 g/L 13C glucose, 4 g/L (NH4)2HPO4, 2.8 g/L KH2PO4, 7.4 g/L 
K2HPO4, 0.5 g/L MgSO4, 2.5 mg/L CoCl2·6H2O, 15.0 mg/L MnSO4·4H2O, 
1.5 mg/L CuSO4·2H2O, 3 mg/L H3BO3, 2.5 mg/L Na2MoO4·2H2O, 13 mg/L 
Zn(CH3COO)2, 60 mg/L Fe(III) citrate and 8.4 mg/L EDTA.  
E coli. K-12 MG1655 ǻUHF$ǻHQG$ '( (MG1655) were used as the 
parental strain in the experiments. The plasmid pBAD-xylB and pACM-
dxs-idi-ispA-ADS were transformed into the MG1655 strain (MG001). The 
plasmid pBAD-xylB and pACM-dxs-dxr-idi-ispA-ADS were transformed 
into MG1655 strain (MG002).  
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6.5.2 Cultivation and sampling 
The MC media was inoculated by 1% cell culture that was grown in 13C 
glucose media overnight. The cells were cultivated at 37 °C with 300 rpm 
and the culture temperature was shifted to 28 °C after induction. The cells 
were induced when the OD reached ~0.5 by 0.01 mM IPTG and 10 mM 
m-toluic acid (or 10 mM L-arabinose). About two hours later, when the OD 
reached ~2.0 and the enzymes DXP synthase and D-xylulokinase were 
expressed, 0.2 g/L 12C DX was added into the culture. After about 20 
minutes, seven samples were collected every 30 min. The concentration 
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Figure 6-9. The experiment procedure for the kinetics study. 
The samples were collected between mid-log to late-log phase when the cells was at 
steady state. 
 
6.5.3 Quantification of 13C Glucose and DX in the media  
The culture media was centrifuged at 16,000 g for 1 min and 10 ȝ/
supernatant was transferred into 90 ȝ/ methanol. The solution was well 
mixed and centrifuged to remove the salts in the media, and 80 µL of the 
desalted solution was dried and incubated with 30 µL MOX reagent 
(Thermo Scientific) at 37 °C for 1 hour. Thirty microliter MFTFA + 1% 
TMCS (Thermo Scientific) was subsequently added and incubated at 
37 °C for 1 hour. Samples were centrifuged at 16,000 g for 1 min and 1 µL 
sample was injected into the GC-MS in splite mode with 9:1 split ratio at 
270 °C. Agilent 7890 GC equipped with HP-5ms GC column and Agilent 
MS were used at flow rate 1 mL/min. Oven temperature was held at 
100 °C for 2 mins, and elevated to 300 °C in 4 mins and held at 300 °C for 
3 mins. MS source and quadrupole temperature were 230 °C and 150 °C 
respectively. MS data was acquired in scan mode from 100 to 500 m/z. 
6.5.4 Quantification of intracellular and extracellular 
metabolites 
Cell culture media equivalent to 1 mL OD600 =1.0 cells was withdrawn 
and centrifuged at 16,000 for 2 mins. One hundred microliter supernatant 
(extracellular metabolites) was transferred into 800 µL methanol with 100 
µL double distilled water. The cell pellets (intracellular metabolites) were 
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re-suspened in 200 µL water. The suspension was mixed with 800 µL 
acidic extraction buffer (acetonitrile/ methanol/water 40:40:20 +0.1 M 
formic acid) and incubated at room temperature for 5 mins. All the 
solutions (intracellular and extracellular) were centrifuged at 16,000 g for 1 
min. Seven milligram LC-NH2 resin (SUPELCO) was placed into the resin 
cartridges and the resin was conditioned with 100 µL extraction buffer. All 
the supernatant was transferred into the resin cartridges and was 
centrifuged at 2000 g for 1 min.  The metabolites in the resin were eluted 
with 56 µL 1% NH4OH solution. And pH of eluent was subsequently 
adjusted to acidic (pH = 5) by 3 mL acetic acid. The samples were 
analyzed using the UPLC (Waters ACQUITY UPLC) – (TOF) MS (Bruker 
micrOTOF II) platform. UPLC setting and (TOF) mass spectrometry 
setting was essentially as described [157]. 
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Chapter 7. CONCLUSION AND 
RECOMMENDATION OF FUTURE WORKS 
7.1 General conclusion 
Glucose is the preferred substrate for various fermentation processes, 
however the DXP pathway suffers from low efficiency when using glucose. 
In this study, the PTS was modified which resulted in higher productivity of 
downstream isoprenoids. Half of the PEP, the precursor of the DXP 
pathway, produced from glucose is consumed during glucose 
internalization by the PTS. Replacing the PTS with galP and glk increased 
the intracellular concentration of PEP and significantly enhanced the 
amorpha-4,11-diene (AD) production. Further a systematical pathway 
optimization method was developed EDASPO, and it was demonstrated 
by systematic optimization of the expression of galP-glk, dxs, idi-ispDF 
and ispA-ADS, resulted in more than 550 fold increase in AD production 
from glucose.  
Next, the PTS knockout strategy was combined with statistical media 
optimization to enhance the production of lycopene. Two critical 
ingredients in the media were screened experimentally using factorial 
design. Using response surface method (RSM), the optimal 
concentrations of the two critical ingredients were rapidly identified and the 
lycopene yield was increased by more than 3 fold. The optimized medium 
was superior to all the commonly used complex media or defined media 
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for lycopene production. In addition, it was found that the copy number of 
the plasmid encoding the lycopene biosynthetic genes and the expression 
were increased in the optimized media. The results provided insight into 
the underlying mechanisms of media optimization. 
Many biochemicals and biofuels produced at high concentrations are toxic 
to host organisms. Efflux pump engineering is an effective way to cope 
with the issue. In this thesis, native efflux pumps were screened for the 
AD-producing strain. The outer membrane tolC was found to be closely 
involved in the secretion of AD. The deletion of tolC significantly 
decreased the extracellular production of AD and increased the 
intracellular accumulation of AD. Supplementing certain combinations of 
tolC-related transporter systems increased AD titer significantly. The pump 
engineering approach developed herein can be readily applied to other 
products. 
Lastly, the kinetics of the DXP pathway was studied in this thesis. The 
semi-closed dual -flux platform (SCDFP) was developed and optimized. 
Using this platform, the kinetic data of the DXP pathway were successfully 
obtained. It was found that the effluxes of DXP and MEC were closely 
related to their intracellular concentrations. The platform and knowledge 
obtained here is invaluable to understand the regulatory mechanisms of 
the pathway and to better engineer the DXP pathway in the future. 
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7.2 Recommendation of future works 
In this thesis, the native transporters were studied for the efflux of two 
isoprenoids, lycopene and AD. The tolC-related transporters were able to 
enhance the efflux and the yield of AD. However, none of them was able 
to export lycopene, a very hydrophobic compound. As the accumulation of 
high concentration lycopene is very toxic to E. coli and this severely limits 
further improvement of lycopene production, it would be useful to screen 
or engineer a novel transporter for lycopene. We propose to evolve the 
high lycopene-producing strains in microfluidic devices with organic layer 
such as decane which can capture the exported lycopene. The 
microfluidic screening and assay system developed by Stephanopoulos’s 
lab is perfect for this kind of study in which individual cells was 
compartmentalized for growth and analysis in monodisperse nanoliter 
aqueous droplets surrounded by an immiscible fluorinated oil phase [194]. 
Following that, a microarray or sequencing study on the mRNA or gene 
expression profiling will be carried out on those cells capable of secreting 
lycopene, and gained information can lead to novel discovery of efflux 
pumps for lycopene and other carotenoids. 
The kinetics of the DXP pathway was investigated for the first time using 
the semi-closed platform designed in the thesis. Whereas the offline 
quantification method was not ideal for metabolic flux analysis as the time 
points interval was relatively protracted. In order to improve on the 
platform, online monitoring approach can be integrated in the future. Such 
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in vivo 13C nuclear magnetic resonance or the MS-base quantitative real-
time analysis system [191] have already been successfully used in other 
studies and may be useful for this endeavor. For example, bacterial cells 
will be grown and disrupted online, and the lysed cells were centrifuged 
and filtered through automation devices, and the resulting cell free extract 
is analyzed MS-based system. 
In addition, the kinetic model can be further refined as the relationship 
between the efflux rates of metabolites and their intracellular 
concentrations are different from the relationship between the fluxes and 
chemical reactions. The complexity of the kinetics model makes the 
equations stiff and hence, it is very difficult to accurately estimate the 
parameters without deconvoluting the equations. Therefore, in the future, 
the decoupling strategy such as slope-estimation-decoupling or global 
stochastic search algorithm such as evolutionary computation technique 
can be investigated. The constructed mathematical model will be 
invaluable for model analyses and generation and testing of new 
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